

**Division of Medicaid
Office of the Governor
State of Mississippi
Drug Utilization Review (DUR) Board Meeting
August 2011**



**August 18, 2011 at 2:00pm
Woolfolk Building, Room 117
Jackson, MS**

Prepared by:
The University of Mississippi School of Pharmacy
Evidence-Based DUR Initiative, MS-DUR

MS | DUR

Drug Utilization Review Board

Gera Bynum, R.Ph.
Pharmacy Director, Scott Regional Hospital
371 Highway 13S
Morton, MS 39117
Term Expires: June 30, 2012

Lee Merritt, R.Ph.
Medfusion
2211 5th Street North
Columbus, MS 39705
Term Expires: June 30, 2013

Jason Dees, D.O.
New Albany Medical Group
West Longview Drive
New Albany, MS 38652
Term Expires: June 30, 2012

Paul Read, Pharm.D.
CVS Pharmacy #5744
3910 Hardy Street
Hattiesburg, MS 39402
Term Expires: June 30, 2012

Edgar Donahoe, M.D. (Co-Chair)
Indianola Family Medicine Group
122 Baker Street
Indianola, MS 38751
Term Expires: June 30, 2013

Mark Reed, M.D. (Chair)
University of MS Medical Center
2500 North State Street, Trailer 16
Jackson, MS 39216
Term Expires: June 30, 2013

Laura Gray, M.D.
905 Garfield Street
Tupelo, MS 38801
Term Expires: June 30, 2012

Dennis Smith, R.Ph.
Polk's Discount Pharmacy
1031 Star Rd
Brandon, MS 39042
Term Expires: June 30, 2014

Antoinette M. Hubble, M.D.
McComb Children's Clinic
300 Rawls Dr. Ste 100
McComb, MS 39648
Term Expires: June 30, 2014

Cynthia Undesser, M.D.
MS Children's Home Services
402 Wesley Ave
Jackson, MS 39202
Term Expires: June 30, 2014

Cherise McIntosh, Pharm.D.
UMC Dept of Pharmacy
2500 North State St.
Jackson, MS 39216
Term Expires: June 30, 2014

Vicky Veazey, R.Ph.
MS State Hospital, Bldg 50
Whitfield, MS 39193
Term Expires: June 30, 2013
Vicky Veazey, R.Ph.

Upcoming DUR Board Meeting Dates

November 17, 2011

MISSISSIPPI DIVISION OF MEDICAID
OFFICE OF THE GOVERNOR
DRUG UTILIZATION REVIEW BOARD
AGENDA

August 18, 2011

Welcome	Mark Reed, M.D. (Chair)
Old Business	Mark Reed, M.D. (Chair)
Approval of February 2011 Meeting Minutes	
Approval of May 2011 Meeting Minutes	
Resource Utilization Review	Kyle D. Null, Pharm.D.
Pharmacy Program Update	Judith Clark, R.Ph.
DUR Process and DUR Board Responsibilities	
New Business	Kyle D. Null, Pharm.D.
Overview of Medical and POS Billings	
High Dose Abilify® (aripiprazole) Prescribing	
Mental Health Treatment in Pediatric Beneficiaries	
Potential Prescribing Outside of Prescriptive Authority	
Exceptions Monitoring Criteria Recommendations	
Next Meeting Information	Mark Reed, M.D. (Chair)

Mississippi Division of Medicaid
Drug Utilization Review (DUR) Board
Minutes of the May 19, 2011 Meeting

DUR Board Members:	Present	Absent
Gera Bynum, R.Ph.	✓	
Jason Dees, D.O.		✓
Alvin Dixon, R.Ph.		✓
Edgar Donahoe, M.D. (Co-Chair)	✓	
Laura Gray, M.D.		✓
Lee Merritt, R.Ph.	✓	
Paul Read, Pharm.D.		✓
Mark Reed, M.D. (Chair)	✓	
Jason Strong, Pharm.D.		✓
Vicky Veazey, R.Ph.	✓	
Frank Wade, M.D.		✓
Total	5	6

Also Present:

DOM Staff: Judith Clark, R.Ph., DOM Pharmacy Bureau Director; Shannon Hardwick, R.Ph., DOM Clinical Pharmacist; Terri Kirby, R.Ph., DOM Clinical Pharmacist

MS-DUR Staff: Kyle Null, Pharm.D., Clinical Director; Ben Banahan, Ph.D., Project Director; Thomas Chapman, M.S., Analyst

ACS Staff: Leslie Leon, Pharm.D.

Visitors: Terry Threadgill, Takeda; David Mershon, BMS; Mike Birdsong, Bayer; Marcus Kirby, Takeda; Dan Barbera, Lilly; Eleanor Young, Boehringer-Ingelheim; Pat Harvey, Sunovion

Call to Order: Dr. Mark Reed, Chairman of the Board, called the meeting to order at 2:06 p.m. He acknowledged the DUR Board members who were able to attend the meeting.

Dr. Reed noted that because of the lack of a quorum, approval of the minutes from the DUR Board meeting on February 17, 2011 would be voted on at the August 18, 2011 DUR Board meeting.

Resource Utilization Review:

Overview of Claims Trends Reflecting MississippiCAN Implementation

Dr. Null began the resource utilization review by noting a number of changes to the Division of Medicaid since January 1, 2011, specifically highlighting the movement of selected beneficiaries into the Mississippi Coordinated Access Network (MississippiCAN). Under this new program, two coordinated care organizations, Magnolia Health Plan and UnitedHealthcare are responsible for providing services to targeted Medicaid beneficiaries in certain eligibility categories not to exceed 15% of the total Medicaid population. Dr. Null noted the future DUR

reports would only reflect the fee-for-service (FFS) beneficiaries, unless otherwise specified. Dr. Null also pointed out that the changes in the number of prescription claims and total unique beneficiaries with a prescription claim between September 2010 and March 2011 may be reflective of beneficiary movement between Medicaid FFS and MississippiCAN. Dr. Donahoe mentioned that the upward trend from January 2011 to March 2011 could be due to beneficiaries moving back into Medicaid FFS, possibly because of their lack of awareness of being auto-enrolled into the MississippiCAN programs. In particular, Figure 1 from the “Claims Trends” section was mentioned, bringing attention to the drop in January claims being notably greater than normal for the first of the year. Much of the drop is hypothesized to be MS CAN movement. Ms. Clark commented on a request to make these tables 3 year rolling numbers and to include previous year’s data when presenting information so that DOM and the DUR Board are not looking at these values in a “silo.” Dr. Null concurred. Dr. Null concluded by adding that the dollar amounts presented in the DUR report were only reflective of reimbursement amounts to Medicaid providers and not of overall costs to Medicaid.

Synagis® (palivizumab) Details for the 2010-2011 RSV Season

Dr. Null began the Synagis® update by reviewing the total reimbursed claims and unique beneficiaries receiving Synagis® during this last RSV season (ending in March). Dr. Null pointed out that Medicaid pays for up to 5 injections for beneficiaries under 24 months of age who meet the prior authorization criteria. Given that criteria, a small number of cases were identified where the count of injections was over 5 and the age at the time of injection was greater than 24 months. MS-DUR turned these cases over to the Division of Medicaid to review.

Ms. Clark reminded the Board that as of January 1, 2011, the prior authorization process is being handled by the Division of Medicaid, with about 90+% of the Synagis PAs being handled by DOM. Ms. Clark said there will be ongoing quality assurance efforts to address these issues.

Dr. Reed then asked Ms. Clark to provide the pharmacy program update.

Pharmacy Program Update:

Ms. Clark mentioned that the new preferred drug list (PDL) will be effective on July 1, 2011 and a link will be posted on the Mississippi Medicaid website by June 1, 2011. Ms. Clark noted that the DOM concurs with the Pharmacy and Therapeutics (P&T) Committee’s recommendations anywhere from 85 to 95% of the time, depending on a number of situations. Ms. Clark mentioned that the possible addition of some prenatal vitamins to the PDL would be addressed in an upcoming P&T meeting. Ms. Clark then brought up the recent withdrawal of certain unapproved prescription cough and cold products and noted that Medicaid is currently revising the over-the-counter formulary to address this through collaboration with the University of Mississippi School of Pharmacy. Ms. Clark noted that the entire OTC formulary would not be revised, but cough and cold products would be revisited, as well as certain other products.

Ms. Clark mentioned that DOM was continuing to integrate the prior authorization process into SmartPA® and asked for feedback from the DUR Board on how the PA process was progressing. Dr. Donahoe commented that his office was not utilizing prior authorizations much and Mr.

Merriitt added that his staff has not mentioned any issues since the MississippiCAN implementation. Ms. Clark pointed out that the length of time allowed for diagnoses and prior prescriptions in the SmartPA® clinical edits process was increased from 13 months to 2 years in an effort to increase the likelihood of finding information to satisfy the clinical edit, but there was still a lack of appropriate diagnoses codes found in the medical data.

Resource Utilization Report (continued):

Dr. Null continued with the resource utilization report, noting several outlying categories of drugs before and after the MississippiCAN implementation. Dr. Null noted the utilization of atypical antipsychotics and anticonvulsants decreasing more than expected, with much of this likely due to beneficiary movement into MississippiCAN. Dr. Null also pointed out that the downward trends in the dollar figures reflected in the report should not necessarily be interpreted as savings to the Medicaid program, noting that Mississippi Medicaid pays a capitated rate to the CCOs for the beneficiaries enrolling in the MississippiCAN program. Ms. Clark concurred and added that the report only represents shifts in the current FFS beneficiary population. Dr. Null brought the Board's attention to the prenatal vitamin detail report and pointed out that the prenatal vitamins would be addressed in a future P&T meeting to explore the possibility of identifying preferred products for inclusion on the PDL.

Ms. Clark suggested changing the resource utilization format to 3 months per page in landscape and listing the top individual drug for each class on the category report. Dr. Null concurred and requested feedback on other parts of the report to make it more useful for the DUR Board.

New Business

FDA Action: Withdrawal of Unapproved Prescription Cough and Cold Products

Dr. Null began by reviewing the recent FDA changes, including a brief history of OTC cough and cold product labeling changes over the last few years. Dr. Null briefly reviewed the literature identifying that much of the past safety concerns had to do with misuse rather than product safety; however, many of the products do not have strong safety or efficacy data. Dr. Null pointed out the Appendix to the DUR packet, which included the list maintained by the FDA of unapproved prescription cough and cold products that will be withdrawn from the market in September 2011.

Ms. Clark explained problems that Medicaid has with this recent withdrawal notice. If the pharmaceutical company participates in rebate program, Medicaid has to cover their products unless the product is in specific classes not required (SSA Section 1927 drugs) – even if product has not been formally approved. Companies can reformulate and reduce strength to meet OTC monograph; however, OTCs do not have to be covered. In this case, the product keeps the same name but moves from legend to OTC. Medicaid does not have to cover the drug when it is an OTC. Notice from CMS changes products to non-covered status “immediately” upon receipt of the letter; otherwise, the State must fully pay for the product without the Federal match. The DOM works with a fiscal agent to change coverage status as quickly as possible due to fiscal liability after notification. Dr. Null pointed out the current utilization of cough and cold products for beneficiaries, stratified by age.

Ms. Clark requested comments from the DUR Board regarding this issue and asked about including saline nasal spray to the OTC formulary. Dr. Donahoe indicated he thought it was already covered and also indicated he has been writing prescriptions for Tyzine, a nasal decongestant, and it has been covered by DOM. Ms. Clark mentioned that was not the case, but it would be a good option to add. Dr. Reed noted he does not prescribe nasal decongestants (limited to 3 days) much but does use saline spray. Considering the minimal cost for saline nasal spray, adding this to the OTC formulary would be a good option. Dr. Reed discussed using a decongestant without an antihistamine in young children and infants, noting that you really do not want to use an antihistamine because of the problem with thickening nasal secretions – saline and decongestant are preferred. Ms. Clark suggested pairing Dr. Reed with someone to write a short article or journal piece about the best way to treat infants with colds. Dr. Reed concurred.

Coordination of Pharmacy and Medical Claims for Drug Products:

Dr. Null introduced the analysis conducted to determine the prevalence of double billing (i.e., billing on both the medical and the pharmacy sides) may be and can claims be used to monitor comparable payments in both systems Dr. Null pointed out that identification of duplicate billing cases is difficult due to misuse of J-Codes, resulting in amounts billed for much less than the drug cost – possibly reflecting billing for administration or supplies using the J-code. The initial analysis does not indicate that duplicate billing frequently occurs. MS-DUR identified a potential algorithm to be used to identify possible double billing and will work with the DOM Pharmacy Bureau and Program Integrity on this issue. Ms. Clark noted that DOM and MS-DUR will look at other Medicaid programs to see how they are implementing this identification process. No DUR board recommendation is requested at this time.

Lupron® (leuprolide) Use for Short Stature:

Dr. Null reviewed the background on Lupron® being prescribed for short stature. Dr. Null mentioned that this issue was brought to MS Medicaid's attention due to notices on Medicaid Director e-mail list that indicated other states had identified this as a potential issue. After running the analysis, no suspicious cases were identified and no further actions were recommended.

Therapeutic Criteria Exceptions Monitoring and Educational Program:

Dr. Null reviewed the regulations related to retrospective drug utilization review found in the Code of Federal Regulations. Dr. Null reviewed the functions of monitoring and intervention activities and mentioned that future DUR Board meetings would include therapeutic criteria monitoring to be submitted for approval from the Board.

Ms. Clark initiated discussion of using clinical articles as an educational approach and doing cost-saving estimates based on these efforts rather than a letter-based campaign, which was how the educational interventions were handled in the past. Ms. Clark mentioned that she does not want the DUR program to be perceived as being punitive in nature. Dr. Reed suggested sending e-mails rather than letters to be more cost effective. Dr. Null asked when an individual communication from MS-DUR or from DUR would be useful. Dr. Reed commented that the

message must be short, containing bullet points, and easy and quick to read. Dr. Donahoe pointed out that finding the time to read the communication is an issue, but that anything that the provider would not otherwise know about the patient would be welcome and useful. Dr. Donahoe also noted that if there is something that is clearly harmful or inappropriate, it can be handled at the point of sale with a clinical edit rather than through a letter or email communication. Ms. Clark and Dr. Null concurred.

Dr. Reed mentioned that an effort would need to be made to distinguish general information from patient-specific information. Dr. Donahoe mentioned that the information from MS-DUR should be patient-specific in order to be maximally helpful. Dr. Null inquired about the usefulness of providing patient-specific information on medication adherence issues, and patients receiving multiple medicines from different providers, including information that providers can incorporate into the patient's medical record. Various members of the DUR Board collectively agreed that these types of efforts would be of value for educational outreach.

Ms. Clark inquired about the potential of MS-DUR providing Medicaid providers with controlled substances reports and other patient-specific pharmacy and medical information to support the provider's decision making. Dr. Reed said that this type of information would be extremely helpful. Dr. Donahoe concurred and mentioned that any information that providers would not normally have routine access to would be helpful for MS-DUR to pursue.

Dr. Null asked the same questions to the pharmacists, specifically asking whether any information provided would be useful and actionable. Mr. Merritt commented that information on adherence would probably be useful, but not actionable based on the current workload and workflow of pharmacists. Ms. Bynum commented that the current workflow of many pharmacies is not setup to receive and file such patient-specific information due to the lack of physical charts and limited notes sections on the pharmacy software.

Ms. Clark discussed provider access to the prescription drug monitoring program. MS DUR will begin to develop an e-mail database for prescribers and begin moving forward with the directives mentioned during the discussion.

***Helicobacter pylori* Prior Authorization Protocol:**

Dr. Null began to review the current *H. pylori* prior authorization process that Mississippi Medicaid uses and briefly reviewed the current treatment guidelines for the treatment of *H. pylori*. Dr. Donahoe believes the current recommendation provided by MS-DUR to relax the one prescription limit and to allow for two *H. pylori* agents is appropriate and covers the need of the beneficiaries. Dr. Reed mentioned bringing this issue back for vote at the next meeting to make official, but DOM would begin to work off of this discussion.

Other Business

Ms. Clark mentioned that several DUR Board member's terms will expire on June 30, 2011 – William Bastian, Alvin Dixon, Jason Strong, and Frank Wade. Ms. Clark thanked them for their service and emphasized the importance of the DUR Board members to Medicaid. Ms. Clark also

commented that the DOM is working on getting recommendations for new members approved and that they are striving to create a diverse DUR Board and P&T Committee, both demographically and in practice areas. Ms. Clark asked Ms. Kirby to review the major DUR recommendations from last year and provide an update on the current status of these recommendations.

Ms. Kirby mentioned several changes DOM hopes to have incorporated into SmartPA® by the August DUR Board meeting:

- Limiting Lovenox® use to 17 days duration of therapy
- Requiring a trial of a statins before allowing a non-statin lipotropic
- ACE-I required before an ARB, data could not support automated decision
- Duplicate therapy on antipsychotics – MS-DUR will provide further analysis and drill down more into the potential 8% of cases that could be duplicate therapy
- Low dose Seroquel® recommendation has been incorporated into SmartPA®
- Requiring a diagnosis of Alzheimer’s disease for medicines used to treat this condition has been incorporated into SmartPA®

Next Meeting Information

Dr. Reed thanked the members rotating off the DUR Board for their service and announced that the next meeting date is August 18, 2011 at 2:00p.m. and thanked everyone for making the effort to attend the DUR Board meeting. The meeting adjourned at 3:28p.m.

Submitted,
Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Top 15 Drug Classes
Top 25 Drug Detail

By Quarter
Amount Paid*

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Antipsychotics (atypical and typical)	\$2,599,294.37	8,200	\$2,103,432.95	6,651	\$5,727,077.27	16,982	\$10,429,804.59	31,833
Aripiprazole	\$875,016.56	1,565	\$713,304.35	1,282	\$1,581,001.23	2,765	\$3,169,322.14	5,612
Quetiapine	\$630,856.99	1,589	\$489,638.70	1,265	\$1,317,017.40	2,974	\$2,437,513.09	5,828
Olanzapine	\$372,420.79	532	\$279,582.20	389	\$824,858.05	1,103	\$1,476,861.04	2,024
Risperidone	\$291,811.90	2,620	\$245,658.79	2,164	\$748,501.37	5,427	\$1,285,972.06	10,211
Ziprasidone	\$194,082.23	456	\$179,129.62	413	\$487,360.59	1,083	\$860,572.44	1,952
Paliperidone	\$133,038.40	158	\$109,306.34	118	\$500,448.02	508	\$742,792.76	784
Asenapine	\$30,591.86	70	\$27,065.82	58	\$66,949.64	145	\$124,607.32	273
Haloperidol	\$22,163.76	401	\$17,154.16	327	\$77,231.39	1,233	\$116,549.31	1,961
Clozapine	\$20,415.86	116	\$17,110.82	95	\$45,013.59	262	\$82,540.27	473
Chlorpromazine	\$8,800.96	264	\$6,524.38	234	\$14,453.16	512	\$29,778.50	1,010
Lurasidone	\$3,656.98	10	\$5,856.05	13	\$10,686.77	22	\$20,199.80	45
Fluphenazine	\$3,688.81	71	\$2,767.09	52	\$12,871.23	266	\$19,327.13	389
Iloperidone	\$1,973.68	4	\$1,997.90	5	\$14,347.12	25	\$18,318.70	34
Perphenazine	\$3,922.52	68	\$3,059.96	50	\$11,134.42	184	\$18,116.90	302
Prochlorperazine	\$2,482.38	168	\$1,479.80	96	\$3,732.92	216	\$7,695.10	480
Loxapine	\$1,248.84	16	\$1,350.54	16	\$4,146.85	49	\$6,746.23	81

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Trifluoperazine	\$1,259.92	28	\$922.33	21	\$2,733.66	58	\$4,915.91	107
Thioridazine	\$1,046.62	35	\$1,027.31	35	\$2,713.82	82	\$4,787.75	152
Thiothixene	\$636.02	26	\$270.65	15	\$1,577.80	64	\$2,484.47	105
Pimozide	\$179.29	3	\$226.14	3	\$298.24	4	\$703.67	10
Adrenals	\$1,268,632.29	13,034	\$903,826.58	9,137	\$1,129,305.55	11,615	\$3,301,764.42	33,786
Budesonide	\$994,946.04	3,532	\$697,652.82	2,398	\$831,387.80	2,840	\$2,523,986.66	8,770
Prednisolone	\$97,231.52	5,488	\$70,318.13	3,822	\$72,042.70	3,827	\$239,592.35	13,137
Budesonide-formoterol	\$48,221.08	234	\$41,023.13	200	\$76,158.65	369	\$165,402.86	803
Fluticasone	\$44,838.95	340	\$34,804.55	261	\$57,347.30	434	\$136,990.80	1,035
Mometasone	\$34,938.46	266	\$24,516.37	182	\$30,015.53	229	\$89,470.36	677
Beclomethasone	\$15,623.68	139	\$12,296.31	103	\$19,884.37	168	\$47,804.36	410
Prednisone	\$7,821.50	1,623	\$6,324.64	1,326	\$9,839.03	2,125	\$23,985.17	5,074
Methylprednisolone	\$7,846.67	769	\$3,422.75	346	\$9,062.24	881	\$20,331.66	1,996
Formoterol-mometasone	\$5,474.82	26	\$3,850.82	19	\$8,866.40	34	\$18,192.04	79
Dexamethasone	\$5,862.39	422	\$4,675.75	326	\$6,618.85	443	\$17,156.99	1,191
Hydrocortisone	\$2,208.96	81	\$1,605.48	56	\$4,631.71	154	\$8,446.15	291
Flunisolide Nasal	\$1,862.01	38	\$2,046.39	38	\$1,455.95	28	\$5,364.35	104
Fludrocortisone	\$1,646.26	63	\$1,150.79	46	\$1,915.04	73	\$4,712.09	182
Triamcinolone	\$94.32	12	\$88.32	12	\$48.72	8	\$231.36	32
Cortisone	\$15.63	1	\$15.63	1	\$31.26	2	\$62.52	4
Betamethasone			\$34.70	1			\$34.70	1

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Hemostatics	\$903,623.08	38	\$1,015,410.50	43	\$1,280,154.31	64	\$3,199,187.89	145
Anti-inhibitor Coagulant Complex	\$345,595.50	5	\$583,631.04	9	\$738,024.22	10	\$1,667,250.76	24
Antihemophilic Factor	\$391,484.89	14	\$280,780.69	13	\$404,255.25	22	\$1,076,520.83	49
Antihemophilic Factor-von Willebrand	\$127,197.27	4	\$149,124.61	9	\$69,787.99	3	\$346,109.87	16
Coagulation Factor Ix					\$63,257.88	4	\$63,257.88	4
Coagulation Factor Viia	\$37,566.22	2					\$37,566.22	2
Tranexamic Acid	\$1,713.24	12	\$1,555.30	10	\$3,117.82	21	\$6,386.36	43
Aminocaproic Acid	\$65.96	1	\$318.86	2	\$1,711.15	4	\$2,095.97	7
Anticonvulsants, Miscellaneous	\$843,447.41	9,188	\$693,743.24	7,472	\$1,631,853.21	17,204	\$3,169,043.86	33,864
Divalproex Sodium	\$160,768.93	1,539	\$130,276.77	1,230	\$329,041.23	3,120	\$620,086.93	5,889
Oxcarbazepine	\$119,819.64	934	\$97,371.73	759	\$246,620.37	1,722	\$463,811.74	3,415
Pregabalin	\$117,036.97	631	\$99,367.50	529	\$204,167.14	1,074	\$420,571.61	2,234
Levetiracetam	\$99,217.18	1,149	\$84,233.61	944	\$182,837.71	2,068	\$366,288.50	4,161
Gabapentin	\$72,786.44	1,941	\$60,103.07	1,590	\$150,359.30	3,747	\$283,248.81	7,278
Lamotrigine	\$73,156.95	852	\$57,071.04	683	\$119,296.76	1,475	\$249,524.75	3,010
Topiramate	\$52,604.27	1,008	\$37,751.27	761	\$97,891.30	1,757	\$188,246.84	3,526
Lacosamide	\$30,977.34	82	\$33,131.77	84	\$81,499.34	183	\$145,608.45	349
Carbamazepine	\$35,827.67	561	\$33,683.46	501	\$73,551.84	1,190	\$143,062.97	2,252
Vigabatrin	\$23,556.78	5	\$11,432.12	2	\$42,891.47	10	\$77,880.37	17
Felbamate	\$18,968.85	25	\$17,918.76	21	\$26,667.93	34	\$63,555.54	80
Rufinamide	\$12,932.80	26	\$11,641.27	24	\$27,087.39	51	\$51,661.46	101

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Zonisamide	\$10,320.45	221	\$7,889.88	187	\$22,249.18	456	\$40,459.51	864
Valproic Acid	\$9,857.83	198	\$7,318.40	148	\$14,852.96	294	\$32,029.19	640
Tiagabine	\$5,341.44	10	\$4,552.59	9	\$12,839.29	23	\$22,733.32	42
Magnesium Sulfate	\$273.87	6					\$273.87	6
Leukotriene Modifiers	\$1,179,579.71	8,269	\$843,100.37	5,909	\$1,143,704.54	7,999	\$3,166,384.62	22,177
Montelukast	\$1,179,106.27	8,264	\$842,817.71	5,906	\$1,142,366.32	7,991	\$3,164,290.30	22,161
Zafirlukast	\$473.44	5	\$282.66	3	\$555.87	6	\$1,311.97	14
Zileuton					\$782.35	2	\$782.35	2
Amphetamines	\$1,054,675.03	6,744	\$768,123.42	4,907	\$1,235,928.72	7,740	\$3,058,727.17	19,391
Amphetamine-dextroamphetamine	\$566,863.24	3,581	\$416,102.04	2,625	\$680,713.56	4,160	\$1,663,678.84	10,366
Lisdexamfetamine	\$481,220.77	3,088	\$345,383.82	2,212	\$546,152.02	3,478	\$1,372,756.61	8,778
Dextroamphetamine	\$6,591.02	75	\$6,637.56	70	\$9,063.14	102	\$22,291.72	247
Antiretrovirals	\$508,691.89	603	\$452,229.24	533	\$1,726,437.20	2,061	\$2,687,358.33	3,197
Efavirenz/emtricitabine/tenofovir	\$113,494.61	69	\$104,081.93	63	\$386,303.53	239	\$603,880.07	371
Emtricitabine-tenofovir	\$65,834.97	60	\$56,241.67	50	\$219,360.78	204	\$341,437.42	314
Atazanavir	\$56,415.06	58	\$48,410.43	50	\$231,317.64	237	\$336,143.13	345
Lopinavir-ritonavir	\$39,560.36	56	\$35,280.26	49	\$117,897.55	166	\$192,738.17	271
Raltegravir	\$24,465.73	25	\$22,833.56	23	\$122,796.12	126	\$170,095.41	174
Lamivudine-zidovudine	\$35,504.38	43	\$39,283.51	46	\$90,029.55	106	\$164,817.44	195
Tenofovir	\$25,010.10	35	\$18,744.13	26	\$95,696.51	135	\$139,450.74	196

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Abacavir-lamivudine	\$17,262.09	19	\$10,584.53	11	\$86,939.47	98	\$114,786.09	128
Ritonavir	\$18,295.99	60	\$15,992.52	51	\$78,074.08	246	\$112,362.59	357
Abacavir/lamivudine/zidovudine	\$26,955.45	19	\$21,363.28	15	\$54,135.28	38	\$102,454.01	72
Efavirenz	\$16,392.79	32	\$15,750.80	30	\$45,451.29	82	\$77,594.88	144
Darunavir	\$13,315.65	13	\$12,262.95	13	\$48,591.98	52	\$74,170.58	78
Abacavir	\$8,565.25	16	\$8,288.80	16	\$35,478.74	72	\$36,149.75	74
Nelfinavir	\$9,131.88	12	\$9,131.88	12	\$15,174.62	20	\$33,438.38	44
Lamivudine	\$6,409.19	25	\$5,574.34	19	\$17,180.07	53	\$29,163.60	97
Fosamprenavir	\$6,990.84	6	\$3,880.39	4	\$15,492.42	16	\$26,363.65	26
Enfuvirtide	\$8,332.56	3	\$8,335.56	3	\$8,251.71	3	\$24,919.83	9
Nevirapine	\$4,803.66	9	\$5,359.63	12	\$13,574.82	32	\$23,738.11	53
Etravirine	\$1,623.64	2	\$2,433.96	3	\$16,768.04	22	\$20,825.64	27
Didanosine	\$2,694.88	12	\$1,933.98	8	\$7,515.87	33	\$12,144.73	53
Maraviroc	\$2,971.53	3	\$2,971.53	3	\$5,902.36	6	\$11,845.42	12
Zidovudine	\$1,087.32	18	\$1,508.23	20	\$4,905.34	58	\$7,500.89	96
Saquinavir	\$931.18	1	\$931.18	1	\$3,724.72	4	\$5,587.08	6
Tipranavir	\$1,109.33	1			\$3,368.52	3	\$4,477.85	4
Stavudine	\$1,050.19	5	\$1,050.19	5	\$1,539.67	8	\$3,640.05	18
Indinavir	\$483.26	1			\$966.52	2	\$1,449.78	3
Anorex., Resp. & Cerebral Stim., Misc.	\$900,235.88	5,424	\$639,749.50	3,948	\$1,084,817.29	6,442	\$2,624,802.67	15,814
Methylphenidate	\$609,669.13	3,451	\$431,938.85	2,529	\$719,820.16	4,090	\$1,761,428.14	10,070

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Dexmethylphenidate	\$280,480.52	1,956	\$201,218.08	1,405	\$349,202.87	2,326	\$830,901.47	5,687
Modafinil	\$9,012.21	13	\$5,051.52	9	\$11,265.80	16	\$25,329.53	38
Armodafinil	\$924.63	3	\$1,541.05	5	\$2,588.14	8	\$5,053.82	16
Caffeine	\$149.39	1			\$1,940.32	2	\$2,089.71	3
Metaproterenol	\$11.02	1			\$9.25	1	\$20.27	2
Proton-pump Inhibitors	\$634,575.15	5,730	\$527,968.87	4,652	\$1,002,742.30	9,887	\$2,165,286.32	20,269
Lansoprazole	\$308,706.97	1,684	\$253,846.50	1,347	\$406,122.28	2,307	\$968,675.75	5,338
Omeprazole	\$158,179.30	2,875	\$134,328.08	2,344	\$320,774.48	5,680	\$613,281.86	10,899
Dexlansoprazole	\$138,284.17	1,069	\$114,647.25	873	\$206,558.53	1,595	\$459,489.95	3,537
Amoxicillin/clarithromycin/lansoprazol	\$19,603.03	47	\$17,372.05	41	\$32,517.04	78	\$69,492.12	166
Esomeprazole	\$7,975.65	40	\$5,917.26	33	\$30,284.68	153	\$44,177.59	226
Pantoprazole	\$765.54	11	\$504.54	9	\$5,159.12	69	\$6,429.20	89
Rabeprazole	\$885.81	3	\$885.81	3	\$1,326.17	5	\$3,097.79	11
Omeprazole-sodium Bicarbonate	\$174.68	1	\$467.38	2			\$642.06	3
Insulins	\$566,236.12	2,868	\$469,368.95	2,339	\$999,713.06	5,080	\$2,035,318.13	10,287
Insulin Glargine	\$161,151.90	784	\$126,406.03	614	\$295,446.37	1,446	\$583,004.30	2,844
Insulin Aspart	\$129,770.62	552	\$116,822.29	468	\$193,217.11	786	\$439,810.02	1,806
Insulin Aspart-insulin Aspart Protamin	\$91,366.68	272	\$76,536.01	216	\$182,364.71	559	\$350,267.40	1,047
Insulin Detemir	\$64,314.55	294	\$48,151.74	237	\$107,197.63	511	\$219,663.92	1,042
Insulin Isophane-insulin Regular	\$46,565.27	317	\$39,811.64	269	\$108,821.64	780	\$195,198.55	1,366
Insulin Isophane	\$35,994.81	339	\$27,496.85	270	\$61,899.45	565	\$125,391.11	1,174

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Insulin Regular	\$22,468.04	245	\$18,843.31	204	\$31,361.99	352	\$72,673.34	801
Insulin Lispro	\$10,569.23	49	\$12,096.14	48	\$12,855.96	54	\$35,521.33	151
Insulin Lispro-insulin Lispro Protamine	\$2,452.58	8	\$1,728.37	6	\$3,104.21	11	\$7,285.16	25
Insulin Glulisine	\$1,582.44	8	\$1,476.57	7	\$3,443.99	16	\$6,503.00	31
Beta-Adrenergic Agonists	\$649,173.98	11,070	\$469,740.30	7,852	\$864,525.08	12,488	\$1,983,439.36	31,410
Albuterol	\$347,680.04	9,630	\$246,490.29	6,766	\$376,864.77	10,173	\$971,035.10	26,569
Fluticasone-salmeterol	\$244,559.12	1,117	\$183,720.46	847	\$380,180.69	1,702	\$808,460.27	3,666
Albuterol-ipratropium	\$40,891.41	207	\$30,648.08	156	\$86,791.80	434	\$158,331.29	797
Levalbuterol	\$11,635.80	51	\$5,786.03	35	\$14,743.32	75	\$32,165.15	161
Formoterol	\$1,299.60	8	\$1,210.38	8	\$2,647.07	17	\$5,157.05	33
Terbutaline	\$1,729.80	46	\$1,216.42	36	\$2,172.38	78	\$5,118.60	160
Pirbuterol	\$1,367.19	10	\$668.64	4	\$961.86	7	\$2,997.69	21
Salmeterol					\$153.94	1	\$153.94	1
Metaproterenol	\$11.02	1			\$9.25	1	\$20.27	2
Antineoplastic Agents	\$604,195.92	1,324	\$496,725.06	1,182	\$849,756.24	2,779	\$1,950,677.22	5,285
Leuprolide	\$105,258.84	86	\$96,233.40	82	\$107,331.86	82	\$308,824.10	250
Sorafenib	\$67,047.68	8	\$50,285.76	6	\$117,333.44	14	\$234,666.88	28
Erlotinib	\$57,944.58	13	\$44,544.25	9	\$77,700.51	17	\$180,189.34	39
Histrelin	\$32,008.60	2	\$64,017.20	4	\$32,008.60	2	\$128,034.40	8
Imatinib	\$30,802.54	6	\$30,802.54	6	\$59,639.04	12	\$121,244.12	24
Megestrol	\$25,749.94	236	\$22,751.66	208	\$61,898.96	486	\$110,400.56	930

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Letrozole	\$30,407.88	62	\$23,802.80	54	\$49,038.88	138	\$103,249.56	254
Capecitabine	\$19,956.82	8	\$17,400.45	9	\$47,314.68	22	\$84,671.95	39
Everolimus	\$41,320.22	6	\$27,714.52	4	\$13,605.70	2	\$82,640.44	12
Lapatinib	\$22,256.50	6	\$14,307.88	4	\$44,513.00	12	\$81,077.38	22
Anastrozole	\$21,377.84	88	\$16,445.86	76	\$41,318.40	176	\$79,142.10	340
Sunitinib	\$17,397.66	2	\$14,661.86	4	\$33,104.72	4	\$65,164.24	10
Methotrexate	\$14,257.36	568	\$14,067.72	532	\$34,454.88	1,260	\$62,779.96	2,360
Nilotinib	\$8,064.49	1	\$16,128.97	2	\$31,736.69	4	\$55,930.15	7
Temozolomide	\$26,697.37	8	\$5,894.12	3	\$23,178.31	6	\$55,769.80	17
Bevacizumab	\$14,794.77	3	\$9,863.18	2	\$17,260.10	3	\$41,918.05	8
Topotecan	\$14,954.88	4	\$6,507.42	1			\$21,462.30	5
Tamoxifen	\$4,800.32	98	\$3,991.26	82	\$10,745.90	226	\$19,537.48	406
Paclitaxel Protein-bound	\$8,868.14	1	\$8,868.14	1			\$17,736.28	2
Dasatinib	\$8,324.04	1			\$8,324.04	1	\$16,648.08	2
Vorinostat	\$9,843.62	1			\$4,922.27	1	\$14,765.89	2
Hydroxyurea	\$2,236.67	44	\$1,263.85	26	\$9,716.86	166	\$13,217.38	236
Mercaptopurine	\$2,676.68	28	\$2,215.36	25	\$5,962.93	64	\$10,854.97	117
Exemestane	\$2,749.88	8	\$1,300.58	4	\$6,476.16	18	\$10,526.62	30
Bicalutamide	\$2,561.68	24	\$2,812.94	28	\$4,496.06	44	\$9,870.68	96
Aldesleukin	\$8,230.18	2					\$8,230.18	2
Fulvestrant	\$1,748.44	2			\$1,748.44	2	\$3,496.88	4
Interferon Alfa-2b					\$2,658.02	2	\$2,658.02	2

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Cyclophosphamide	\$270.02	2	\$542.53	4	\$1,233.97	8	\$2,046.52	14
Etoposide					\$1,567.34	2	\$1,567.34	2
Tretinoin	\$1,203.24	1					\$1,203.24	1
Fluorouracil	\$267.93	2	\$96.86	2	\$224.49	3	\$589.28	7
Chlorambucil			\$109.00	1	\$109.00	1	\$218.00	2
Thioguanine	\$53.81	1			\$132.99	1	\$186.80	2
Cytarabine	\$63.30	2	\$94.95	3			\$158.25	5
Opiate Agonists	\$455,035.65	22,482	\$365,766.43	17,993	\$882,505.73	38,887	\$1,703,307.81	79,362
Acetaminophen-hydrocodone	\$192,841.99	13,569	\$158,041.43	11,118	\$422,218.53	25,213	\$773,101.95	49,900
Fentanyl	\$82,878.37	342	\$64,581.85	272	\$137,116.79	540	\$284,577.01	1,154
Acetaminophen-oxycodone	\$51,768.62	1,872	\$42,281.96	1,522	\$80,412.36	2,645	\$174,462.94	6,039
Morphine	\$44,235.27	358	\$34,230.64	280	\$84,980.23	763	\$163,446.14	1,401
Oxycodone	\$20,440.06	192	\$17,811.76	156	\$65,385.85	523	\$103,637.67	871
Acetaminophen-codeine	\$26,526.31	3,198	\$19,781.56	2,404	\$33,435.29	3,932	\$79,743.16	9,534
Tramadol	\$11,389.95	2,023	\$8,669.12	1,527	\$25,353.00	4,104	\$45,412.07	7,654
Acetaminophen-tramadol	\$8,327.75	298	\$6,329.42	222	\$7,733.60	270	\$22,390.77	790
Hydrocodone-ibuprofen	\$6,837.77	267	\$5,248.02	210	\$7,212.35	270	\$19,298.14	747
Apap/caffeine/dihydrocodeine	\$4,136.17	94	\$3,564.41	89	\$4,074.56	91	\$11,775.14	274
Oxymorphone	\$2,032.50	5	\$2,743.09	6	\$3,932.47	9	\$8,708.06	20
Hydromorphone	\$1,442.62	68	\$733.56	40	\$3,744.56	135	\$5,920.74	243
Meperidine	\$1,261.11	111	\$915.13	73	\$2,377.05	160	\$4,553.29	344

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Methadone	\$636.83	74	\$461.73	56	\$2,134.04	167	\$3,232.60	297
Aspirin-oxycodone	\$233.50	9	\$278.45	12	\$474.68	21	\$986.63	42
Asa/butalbital/cafeine/codeine					\$889.11	14	\$889.11	14
Apap/butalbital/cafeine/codeine	\$35.44	1	\$62.70	2	\$716.23	17	\$814.37	20
Tapentadol					\$215.43	1	\$215.43	1
Codeine			\$31.60	4	\$99.60	12	\$131.20	16
Acetaminophen-propoxyphene	\$11.39	1					\$11.39	1
Corticosteroids	\$625,991.96	6,388	\$435,768.44	4,506	\$619,155.26	7,060	\$1,680,915.66	17,954
Mometasone Nasal	\$355,533.83	3,159	\$238,211.54	2,128	\$242,755.14	2,145	\$836,500.51	7,432
Ciprofloxacin-dexamethasone Otic	\$115,965.77	890	\$89,546.95	688	\$194,813.73	1,470	\$400,326.45	3,048
Fluticasone Nasal	\$98,774.54	972	\$64,098.49	627	\$102,465.40	1,264	\$265,338.43	2,863
Hydrocortisone/neomycin/polymyxin	\$14,817.80	550	\$11,414.52	425	\$32,022.74	1,192	\$58,255.06	2,167
Dexamethasone-tobramycin Ophthal	\$20,686.78	264	\$15,657.78	212	\$21,796.27	290	\$58,140.83	766
Dexamethasone/neomycin/polymyxin	\$4,992.77	230	\$3,548.72	174	\$4,698.31	236	\$13,239.80	640
Hydrocortisone/neomycin/polymyxin	\$3,149.80	43	\$2,114.96	28	\$5,170.30	68	\$10,435.06	139
Loteprednol Ophthalmic	\$2,420.06	24	\$2,669.21	21	\$3,854.82	34	\$8,944.09	79
Tobramycin Ophthalmic	\$2,261.10	271	\$2,216.04	192	\$2,289.72	223	\$6,766.86	686
Prednisolone Ophthalmic	\$1,963.34	128	\$1,419.96	88	\$3,245.71	212	\$6,629.01	428
Flunisolide Nasal	\$1,862.01	38	\$2,046.39	38	\$1,455.95	28	\$5,364.35	104
Ciprofloxacin-hydrocortisone Otic	\$1,340.30	10	\$1,071.64	8	\$1,741.69	13	\$4,153.63	31
Acetic Acid-hydrocortisone Otic	\$948.80	6	\$896.63	6	\$1,290.98	9	\$3,136.41	21

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Prednisolone-sulfacetamide Sodium O	\$471.32	14	\$1,441.65	18	\$1,032.18	27	\$2,945.15	59
Colistin/hc/neomycin/thonzonium Oti	\$923.16	12	\$304.72	4	\$1,301.89	18	\$2,529.77	34
Loteprednol-tobramycin Ophthalmic	\$886.47	7	\$399.61	5	\$351.84	3	\$1,637.92	15
Bacitracin/neomycin/polymyxin B Oph	\$575.64	13	\$331.36	7	\$633.76	16	\$1,540.76	36
Fluorometholone Ophthalmic	\$359.58	20	\$372.41	25	\$432.39	29	\$1,164.38	74
Fluocinolone Otic	\$134.72	4	\$128.72	4	\$300.87	9	\$564.31	17
Budesonide Nasal	\$108.81	1	\$326.43	3			\$435.24	4
Dexamethasone Ophthalmic	\$145.84	6	\$41.60	2	\$156.93	7	\$344.37	15
Bacitracin/hc/neomycin/polymyxin B	\$219.56	5			\$114.14	4	\$333.70	9
Triamcinolone Nasal					\$287.54	3	\$287.54	3
Chloroxylonol/hydrocortisone/pramox	\$99.26	2	\$24.49	1	\$94.36	1	\$193.62	3
Beclomethasone Nasal	\$146.58	1					\$146.58	1
Rimexolone Ophthalmic	\$80.06	2			\$40.03	1	\$120.09	3
Gentamicin-prednisolone Ophthalmic	\$29.02	1	\$32.02	1			\$61.04	2
Neomycin/polymyxin B/prednisolone	\$31.04	1					\$31.04	1
Antidepressants	\$416,144.82	11,449	\$340,082.08	9,291	\$749,983.23	20,751	\$1,506,210.13	41,491
Bupropion	\$129,515.26	1,572	\$102,767.14	1,238	\$204,251.98	2,472	\$436,534.38	5,282
Venlafaxine	\$57,016.58	341	\$50,589.99	291	\$121,599.42	787	\$229,205.99	1,419
Desvenlafaxine	\$66,950.26	500	\$51,887.89	389	\$105,262.76	790	\$224,100.91	1,679
Duloxetine	\$25,293.13	138	\$18,921.57	107	\$62,700.18	343	\$106,914.88	588
Mirtazapine	\$18,542.37	480	\$15,671.93	389	\$41,011.39	1,055	\$75,225.69	1,924

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Amount Paid*†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Escitalopram	\$18,693.43	183	\$16,046.24	150	\$34,012.38	310	\$68,752.05	643
Fluoxetine	\$18,555.82	1,232	\$15,126.39	991	\$29,343.77	2,132	\$63,025.98	4,355
Citalopram	\$17,132.58	2,201	\$13,551.07	1,704	\$27,242.15	3,657	\$57,925.80	7,562
Sertraline	\$11,605.58	1,506	\$10,157.91	1,321	\$19,229.40	2,590	\$40,992.89	5,417
Trazodone	\$9,385.25	1,143	\$7,767.72	958	\$19,813.82	2,467	\$36,966.79	4,568
Paroxetine	\$7,515.11	530	\$7,085.08	461	\$17,925.03	1,141	\$32,525.22	2,132
Fluvoxamine	\$6,606.91	76	\$6,775.52	68	\$12,551.41	149	\$25,933.84	293
Fluoxetine-olanzapine	\$6,203.08	11	\$4,803.71	9	\$14,146.34	25	\$25,153.13	45
Doxepin	\$6,453.48	358	\$5,679.08	306	\$12,663.16	732	\$24,795.72	1,396
Imipramine	\$6,755.76	208	\$4,534.22	153	\$7,388.37	264	\$18,678.35	625
Amitriptyline	\$3,670.58	706	\$2,815.64	537	\$7,091.77	1,370	\$13,577.99	2,613
Amitriptyline-perphenazine	\$2,784.23	67	\$2,468.64	58	\$6,465.16	151	\$11,718.03	276
Amitriptyline-chlordiazepoxide	\$1,425.73	28	\$1,465.87	26	\$2,595.67	49	\$5,487.27	103
Nortriptyline	\$1,138.56	141	\$859.27	104	\$1,525.02	193	\$3,522.85	438
Clomipramine	\$732.86	23	\$941.57	26	\$1,829.19	48	\$3,503.62	97
Desipramine	\$78.88	2	\$76.25	2	\$792.17	13	\$947.30	17
Nefazodone	\$89.38	3	\$89.38	3	\$120.36	4	\$299.12	10
Amoxapine					\$277.61	8	\$277.61	8
Protriptyline					\$144.72	1	\$144.72	1

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Aripiprazole	\$875,016.56	1,565	\$713,304.35	1,282	\$1,581,001.23	2,765	\$3,169,322.14	5,612
PDL Abilify	\$872,971.48	1,554	\$710,231.26	1,264	\$1,577,227.61	2,738	\$3,160,430.35	5,556
Abilify Discmelt	\$2,045.08	11	\$3,073.09	18	\$3,773.62	27	\$8,891.79	56
Montelukast	\$1,179,106.27	8,264	\$842,817.71	5,906	\$1,142,366.32	7,991	\$3,164,290.30	22,161
PDL Singulair	\$1,179,106.27	8,264	\$842,817.71	5,906	\$1,142,366.32	7,991	\$3,164,290.30	22,161
Budesonide	\$994,946.04	3,532	\$697,652.82	2,398	\$831,387.80	2,840	\$2,523,986.66	8,770
Budesonide	\$767,469.34	3,004	\$445,960.86	1,794	\$539,651.26	2,150	\$1,753,081.46	6,948
PDL Pulmicort Respules	\$215,849.90	448	\$241,673.64	532	\$278,918.02	600	\$736,441.56	1,580
PDL Pulmicort Flexhaler	\$11,626.80	80	\$10,018.32	72	\$12,818.52	90	\$34,463.64	242
Quetiapine	\$630,856.99	1,589	\$489,638.70	1,265	\$1,317,017.40	2,974	\$2,437,513.09	5,828
PDL Seroquel	\$479,535.15	1,243	\$375,883.75	979	\$990,776.98	2,271	\$1,846,195.88	4,493
PDL Seroquel Xr	\$151,321.84	346	\$113,754.95	286	\$326,240.42	703	\$591,317.21	1,335
Methylphenidate	\$609,669.13	3,451	\$431,938.85	2,529	\$719,820.16	4,090	\$1,761,428.14	10,070
PDL Concerta	\$510,903.97	2,557	\$287,422.77	1,447	\$575,207.39	2,839	\$1,373,534.13	6,843
PDL Metadate Cd	\$49,268.15	307	\$35,621.18	223	\$62,748.21	385	\$147,637.54	915
Methylphenidate Hydrochloride Er			\$75,039.64	421	\$22,098.60	124	\$97,138.24	545
PDL Daytrana	\$30,075.56	176	\$21,168.33	122	\$36,861.76	214	\$88,105.65	512

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
PDL Methylin	\$8,998.84	182	\$6,423.44	144	\$10,625.36	244	\$26,047.64	570
Methylphenidate Hydrochloride	\$4,999.00	183	\$3,342.54	145	\$6,285.32	219	\$14,626.86	547
Ritalin La	\$4,840.88	30	\$2,525.92	16	\$5,186.27	36	\$12,553.07	82
Methylphenidate Hydrochloride Sr	\$502.63	13	\$299.23	9	\$467.67	18	\$1,269.53	40
Methylin Er	\$80.10	3	\$95.80	2	\$339.58	11	\$515.48	16
Anti-inhibitor Coagulant Complex	\$345,595.50	5	\$583,631.04	9	\$738,024.22	10	\$1,667,250.76	24
Feiba Nf	\$229,755.25	4	\$386,733.10	7	\$518,660.64	8	\$1,135,148.99	19
Feiba Vh Immuno	\$115,840.25	1	\$196,897.94	2	\$219,363.58	2	\$532,101.77	5
Amphetamine-dextroamphetamine	\$566,863.24	3,581	\$416,102.04	2,625	\$680,713.56	4,160	\$1,663,678.84	10,366
PDL Adderall Xr	\$480,233.48	2,209	\$349,330.29	1,600	\$584,608.68	2,639	\$1,414,172.45	6,448
Amphetamine-dextroamphetamine	\$56,439.78	1,195	\$42,043.35	882	\$64,750.81	1,338	\$163,233.94	3,415
Amphetamine-dextroamphetamine Er	\$29,862.53	176	\$24,728.40	143	\$31,354.07	183	\$85,945.00	502
Olanzapine	\$372,420.79	532	\$279,582.20	389	\$824,858.05	1,103	\$1,476,861.04	2,024
Zyprexa	\$329,215.86	459	\$242,852.82	341	\$749,943.68	1,007	\$1,322,012.36	1,807
Zyprexa Zydis	\$43,204.93	73	\$36,729.38	48	\$74,914.37	96	\$154,848.68	217
Lisdexamfetamine	\$481,220.77	3,088	\$345,383.82	2,212	\$546,152.02	3,478	\$1,372,756.61	8,778
PDL Vyvanse	\$481,220.77	3,088	\$345,383.82	2,212	\$546,152.02	3,478	\$1,372,756.61	8,778
Risperidone	\$291,811.90	2,620	\$245,658.79	2,164	\$748,501.37	5,427	\$1,285,972.06	10,211
Risperidone	\$241,395.46	2,559	\$199,674.92	2,108	\$526,112.33	5,160	\$967,182.71	9,827
Risperdal Consta	\$50,416.44	61	\$45,983.87	56	\$220,473.14	263	\$316,873.45	380
Risperdal M-tab					\$1,061.46	2	\$1,061.46	2

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Risperdal					\$854.44	2	\$854.44	2
Antihemophilic Factor	\$391,484.89	14	\$280,780.69	13	\$404,255.25	22	\$1,076,520.83	49
Advate Rahf-pfm	\$237,443.45	10	\$181,918.79	9	\$230,279.85	17	\$649,642.09	36
Helixate Fs	\$43,862.12	1	\$40,037.50	1	\$95,184.04	2	\$179,083.66	4
Kogenate Fs With Bioset	\$54,361.72	1	\$17,741.71	1	\$34,791.53	2	\$106,894.96	4
Recombinate	\$26,597.69	1	\$27,286.20	1	\$43,999.83	1	\$97,883.72	3
Xyntha	\$29,219.91	1					\$29,219.91	1
Hemofil-m			\$13,796.49	1			\$13,796.49	1
Multivitamin, Prenatal	\$345,893.10	7,692	\$286,515.90	6,490	\$364,569.10	8,564	\$996,978.10	22,746
Neevo Dha	\$74,149.56	1,236	\$33,095.34	552	\$29,954.32	504	\$137,199.22	2,292
Neevodha	\$9,391.96	182	\$33,073.62	632	\$66,753.24	1,270	\$109,218.82	2,084
Rovin-nv Dha	\$31,333.80	716	\$31,045.98	710	\$27,479.66	628	\$89,859.44	2,054
Prenate Essential	\$24,551.66	314	\$23,385.46	268	\$26,467.12	300	\$74,404.24	882
Prenexa With Dha	\$28,809.74	384	\$16,484.60	222	\$18,932.10	254	\$64,226.44	860
Neevo	\$24,962.82	478	\$16,202.86	308	\$17,137.60	328	\$58,303.28	1,114
Preque 10	\$18,805.20	396	\$13,214.76	276	\$17,684.34	376	\$49,704.30	1,048
Nexa Select With Dha	\$11,575.80	154	\$15,942.48	212	\$19,790.80	264	\$47,309.08	630
Neevo	\$24,962.82	478	\$706.12	12	\$4,753.30	76	\$30,422.24	566
Concept Dha	\$9,847.40	340	\$8,225.08	286	\$11,237.48	388	\$29,309.96	1,014
Zatean-pn Plus	\$8,502.58	150	\$7,281.62	130	\$8,658.54	154	\$24,442.74	434
Pnv-dha	\$8,753.04	166	\$6,845.80	132	\$7,769.38	150	\$23,368.22	448
Prenatal Plus	\$6,712.48	766	\$5,851.10	664	\$9,334.36	1,004	\$21,897.94	2,434
Prenate Elite Plus Iron	\$8,230.64	108	\$7,242.80	84	\$6,320.20	76	\$21,793.64	268

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Pnv Select	\$6,609.84	144	\$5,112.88	112	\$6,809.86	148	\$18,532.58	404
Folcal Dha	\$4,577.00	90	\$5,976.04	118	\$6,102.64	120	\$16,655.68	328
Prefera Ob-one	\$4,568.88	72	\$3,311.08	52	\$6,108.08	98	\$13,988.04	222
Gesticare Dha Dr	\$5,527.48	92	\$4,037.08	64	\$4,264.58	70	\$13,829.14	226
Preferaob+dha	\$3,299.26	74	\$4,071.26	88	\$6,135.06	136	\$13,505.58	298
Natelle One Dha	\$5,003.12	56	\$3,994.16	44	\$4,270.60	46	\$13,267.88	146
Taron-c Dha	\$4,380.72	168	\$3,284.20	128	\$5,514.92	212	\$13,179.84	508
Prenatal Plus	\$6,712.48	766	\$5,851.10	664	\$23.74	2	\$12,587.32	1,432
Pnv- Iron	\$4,149.38	94	\$3,021.84	68	\$4,683.98	106	\$11,855.20	268
Preferaob	\$3,346.74	76	\$3,253.82	70	\$4,893.66	102	\$11,494.22	248
Concept Ob	\$3,612.94	134	\$2,597.88	96	\$3,143.58	118	\$9,354.40	348
Paire Ob Plus Dha	\$2,654.46	70	\$2,372.92	62	\$3,477.16	90	\$8,504.54	222
Pnv-dha Plus Docusate	\$2,397.44	54	\$2,018.68	46	\$3,379.34	76	\$7,795.46	176
Citranatal Assure	\$1,970.08	38	\$1,708.20	34	\$3,546.66	72	\$7,224.94	144
Zatean-pn Dha	\$1,906.14	36	\$1,233.30	24	\$3,834.34	70	\$6,973.78	130
Rovin-nv	\$2,663.04	60	\$1,543.36	36	\$2,001.84	48	\$6,208.24	144
Triveen Ten	\$775.54	22	\$1,238.92	38	\$2,775.40	86	\$4,789.86	146
Citranatal Harmony	\$927.20	18	\$1,605.60	30	\$2,251.44	42	\$4,784.24	90
Prenatal Ad	\$1,512.24	118	\$1,502.66	116	\$1,475.60	116	\$4,490.50	350
Prenaplus	\$1,202.12	114	\$1,205.68	114	\$1,978.50	188	\$4,386.30	416
Zatean-pn	\$1,669.46	36	\$937.90	22	\$1,587.94	36	\$4,195.30	94
Tricare Dha One	\$1,091.52	20	\$1,043.60	20	\$1,490.96	28	\$3,626.08	68
Vol-plus	\$948.30	82	\$966.32	84	\$1,489.08	130	\$3,403.70	296
Folivan-ob	\$1,041.24	42	\$1,123.24	46	\$1,228.76	50	\$3,393.24	138
Prenatal 19	\$694.28	48	\$1,198.54	84	\$1,129.92	82	\$3,022.74	214

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Citranatal 90 Dha	\$628.38	14	\$827.12	18	\$1,200.74	24	\$2,656.24	56
Prenatabs Rx	\$865.12	74	\$690.48	56	\$993.22	86	\$2,548.82	216
Ob Natal One	\$592.40	16	\$898.94	26	\$517.60	14	\$2,008.94	56
Taron-prx Plus Dha	\$791.60	20	\$717.84	18	\$476.92	12	\$1,986.36	50
Natelle One	\$1,119.16	14	\$313.76	4	\$319.76	4	\$1,752.68	22
Vemavite Prx 2	\$372.40	10	\$519.28	16	\$850.72	24	\$1,742.40	50
Citranatal Dha	\$594.48	14	\$371.96	10	\$688.38	18	\$1,654.82	42
Se-natal 19	\$452.20	42	\$352.60	34	\$645.38	62	\$1,450.18	138
Folcaps Omega 3	\$372.94	10	\$299.12	8	\$747.32	20	\$1,419.38	38
Prefera Ob Plus Dha	\$472.00	10	\$377.60	8	\$370.80	10	\$1,220.40	28
Cavan-heme Omega	\$578.92	16	\$322.24	8	\$82.06	2	\$983.22	26
Se-care	\$528.00	22	\$234.00	10	\$214.66	10	\$976.66	42
Citranatal B-calm	\$186.54	6	\$246.90	6	\$456.80	10	\$890.24	22
Gesticare	\$500.00	10	\$94.00	2	\$294.00	6	\$888.00	18
Prenexa	\$353.60	8	\$442.00	10	\$88.40	2	\$884.00	20
Duet Dha Balanced	\$203.60	4	\$435.04	8	\$214.52	4	\$853.16	16
Prenatal Plus Iron	\$337.92	36	\$226.66	24	\$277.36	34	\$841.94	94
Prenatal-u	\$304.74	24	\$152.64	12	\$318.72	26	\$776.10	62
Citranatal Rx	\$219.48	6	\$225.48	6	\$300.64	8	\$745.60	20
Zatean-ch	\$132.64	4	\$331.60	10	\$265.28	8	\$729.52	22
Prenate Plus	\$277.70	32	\$132.46	14	\$301.52	32	\$711.68	78
Pnv-dha Plus	\$89.30	2	\$357.20	8	\$178.60	4	\$625.10	14
Tl-select					\$546.80	8	\$546.80	8
Vinate Care	\$427.58	14			\$117.88	4	\$545.46	18
Triveen-prx Rnf	\$89.90	2	\$179.80	4	\$269.70	6	\$539.40	12

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Ultimatecare One	\$149.60	4	\$222.98	8	\$143.96	4	\$516.54	16
Albuterol	\$347,680.04	9,630	\$246,490.29	6,766	\$376,864.77	10,173	\$971,035.10	26,569
PDL Ventolin Hfa	\$172,461.47	4,157	\$131,836.69	3,202	\$232,506.63	5,704	\$536,804.79	13,063
Albuterol Sulfate	\$173,803.64	5,360	\$114,066.42	3,517	\$143,738.54	4,441	\$431,608.60	13,318
Relion Ventolin Hfa	\$1,038.00	94	\$273.00	26	\$33.00	3	\$1,344.00	123
Lansoprazole	\$308,706.97	1,684	\$253,846.50	1,347	\$406,122.28	2,307	\$968,675.75	5,338
PDL Prevacid Solutab	\$301,729.66	1,629	\$242,214.76	1,273	\$309,554.38	1,630	\$853,498.80	4,532
Lansoprazole	\$6,977.31	55	\$11,631.74	74	\$96,567.90	677	\$115,176.95	806
Cetirizine	\$367,026.00	13,174	\$256,895.64	9,315	\$322,559.22	11,262	\$946,480.86	33,751
Cetirizine Hydrochloride	\$364,646.79	12,919	\$254,975.19	9,113	\$320,638.17	11,040	\$940,260.15	33,072
All Day Allergy	\$1,978.58	238	\$1,498.87	185	\$1,660.62	210	\$5,138.07	633
All Day Allergy Children's	\$400.63	17	\$421.58	17	\$260.43	12	\$1,082.64	46
Ziprasidone	\$194,082.23	456	\$179,129.62	413	\$487,360.59	1,083	\$860,572.44	1,952
PDL Geodon	\$194,082.23	456	\$179,129.62	413	\$487,360.59	1,083	\$860,572.44	1,952
Mometasone Nasal	\$355,533.83	3,159	\$238,211.54	2,128	\$242,755.14	2,145	\$836,500.51	7,432
PDL Nasonex	\$355,533.83	3,159	\$238,211.54	2,128	\$242,755.14	2,145	\$836,500.51	7,432
Dexmethylphenidate	\$280,480.52	1,956	\$201,218.08	1,405	\$349,202.87	2,326	\$830,901.47	5,687
PDL Focalin Xr	\$268,611.76	1,661	\$192,485.01	1,185	\$335,172.89	1,990	\$796,269.66	4,836
Dexmethylphenidate Hydrochloride	\$9,013.36	239	\$7,040.46	186	\$12,082.41	304	\$28,136.23	729
PDL Focalin	\$2,855.40	56	\$1,692.61	34	\$1,947.57	32	\$6,495.58	122

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Azithromycin	\$326,324.39	10,916	\$230,487.10	7,638	\$255,413.87	8,805	\$812,225.36	27,359
Azithromycin	\$246,273.98	7,417	\$179,610.55	5,370	\$181,095.58	5,447	\$606,980.11	18,234
Azithromycin 5 Day Dose Pack	\$75,814.55	3,336	\$48,098.96	2,145	\$70,314.21	3,184	\$194,227.72	8,665
Azithromycin 3 Day Dose Pack	\$3,987.73	158	\$2,777.59	123	\$3,964.33	173	\$10,729.65	454
Fluticasone-salmeterol	\$244,559.12	1,117	\$183,720.46	847	\$380,180.69	1,702	\$808,460.27	3,666
PDL Advair Diskus	\$230,156.81	1,055	\$172,515.09	798	\$354,328.63	1,595	\$757,000.53	3,448
Advair Hfa	\$14,402.31	62	\$11,205.37	49	\$25,852.06	107	\$51,459.74	218
Guanfacine	\$252,063.81	1,534	\$186,475.64	1,115	\$327,171.97	1,954	\$796,447.77	6,842
PDL Intuniv	\$252,063.81	1,534	\$186,475.64	1,115	\$327,171.97	1,954	\$765,711.42	4,603
Guanfacine Hydrochloride	\$8,707.36	660	\$7,360.57	539	\$14,668.42	1,040	\$30,736.35	2,239
Amoxicillin-clavulanate	\$312,455.64	5,840	\$208,669.42	3,940	\$252,250.19	4,681	\$773,375.25	14,461
Amoxicillin-clavulanate	\$304,216.32	5,746	\$204,778.73	3,887	\$247,876.87	4,631	\$756,871.92	14,264
PDL Augmentin	\$7,035.64	80	\$3,790.56	50	\$3,550.82	41	\$13,909.21	168
Amoxicillin-clavulanate Er	\$953.47	11	\$502.06	8	\$2,012.70	22	\$3,405.13	40
Acetaminophen-hydrocodone	\$192,841.99	13,569	\$158,041.43	11,118	\$422,218.53	25,213	\$773,101.95	49,900
Acetaminophen-hydrocodone Bitartrate	\$192,833.42	13,567	\$157,854.69	11,115	\$422,129.18	25,207	\$772,810.29	49,888
Somatropin	\$189,979.39	60	\$168,284.83	53	\$407,515.35	117	\$765,779.57	230
Nutropin Aq Pen 20 Cartridge	\$73,835.05	16	\$92,127.18	20	\$200,218.25	38	\$366,180.48	74
Nutropin Aq Nuspin 10	\$17,920.28	8	\$14,081.95	6	\$54,350.34	19	\$86,352.57	33
Nutropin Aq Pen 10 Cartridge	\$27,464.10	12	\$17,099.46	9	\$25,985.16	13	\$70,548.72	34

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Amount Paid*†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Genotropin	\$13,700.44	4	\$16,230.78	5	\$31,110.75	11	\$61,041.97	20
Genotropin Miniquick	\$20,561.64	8	\$11,416.07	5	\$26,464.19	10	\$58,441.90	23
Saizen	\$18,099.30	3	\$4,936.88	1	\$21,391.85	4	\$44,428.03	8
Tev-tropin	\$9,041.53	2			\$24,435.38	9	\$33,476.91	11
Nutropin Aq Nuspin 5	\$2,227.58	2	\$6,304.97	4	\$11,126.18	7	\$19,658.73	13
Norditropin Nordiflex Pen	\$5,706.31	1	\$5,706.31	1	\$5,706.31	1	\$17,118.93	3
Humatrope	\$298.10	1			\$3,536.54	2	\$3,834.64	3
Omnitrope Pen 10 Cartridge	\$200.00	1	\$200.00	1	\$3,009.17	2	\$3,409.17	4
PDL Nutropin Aq	\$743.83	1					\$743.83	1
Omnitrope Pen 5 Cartridge	\$181.23	1	\$181.23	1	\$181.23	1	\$543.69	3
Paliperidone	\$133,038.40	158	\$109,306.34	118	\$500,448.02	508	\$742,792.76	784
Invega Sustenna	\$73,667.81	61	\$59,435.25	44	\$368,497.62	299	\$501,600.68	404
Invega	\$59,370.59	97	\$49,871.09	74	\$131,950.40	209	\$241,192.08	380

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Top 15 Drug Classes
Top 25 Drug Detail

By Quarter
Number of Claims

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Opiate Agonists	\$455,035.65	22,482	\$365,766.43	17,993	\$882,505.73	38,887	\$1,703,307.81	79,362
Acetaminophen-hydrocodone	\$192,841.99	13,569	\$158,041.43	11,118	\$422,218.53	25,213	\$773,101.95	49,900
Acetaminophen-codeine	\$26,526.31	3,198	\$19,781.56	2,404	\$33,435.29	3,932	\$79,743.16	9,534
Tramadol	\$11,389.95	2,023	\$8,669.12	1,527	\$25,353.00	4,104	\$45,412.07	7,654
Acetaminophen-oxycodone	\$51,768.62	1,872	\$42,281.96	1,522	\$80,412.36	2,645	\$174,462.94	6,039
Morphine	\$44,235.27	358	\$34,230.64	280	\$84,980.23	763	\$163,446.14	1,401
Fentanyl	\$82,878.37	342	\$64,581.85	272	\$137,116.79	540	\$284,577.01	1,154
Oxycodone	\$20,440.06	192	\$17,811.76	156	\$65,385.85	523	\$103,637.67	871
Acetaminophen-tramadol	\$8,327.75	298	\$6,329.42	222	\$7,733.60	270	\$22,390.77	790
Hydrocodone-ibuprofen	\$6,837.77	267	\$5,248.02	210	\$7,212.35	270	\$19,298.14	747
Meperidine	\$1,261.11	111	\$915.13	73	\$2,377.05	160	\$4,553.29	344
Methadone	\$636.83	74	\$461.73	56	\$2,134.04	167	\$3,232.60	297
Apap/caffeine/dihydrocodeine	\$4,136.17	94	\$3,564.41	89	\$4,074.56	91	\$11,775.14	274
Hydromorphone	\$1,442.62	68	\$733.56	40	\$3,744.56	135	\$5,920.74	243
Aspirin-oxycodone	\$233.50	9	\$278.45	12	\$474.68	21	\$986.63	42
Apap/butalbital/caffeine/codeine	\$35.44	1	\$62.70	2	\$716.23	17	\$814.37	20
Oxymorphone	\$2,032.50	5	\$2,743.09	6	\$3,932.47	9	\$8,708.06	20

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Asa/butalbital/caffeine/codeine					\$889.11	14	\$889.11	14
Penicillins	\$473,054.71	20,482	\$311,695.11	14,098	\$380,746.34	17,531	\$1,165,496.16	52,111
Amoxicillin	\$129,468.99	13,044	\$87,523.65	8,994	\$100,693.82	10,803	\$317,686.46	32,841
Amoxicillin-clavulanate	\$312,455.64	5,840	\$208,669.42	3,940	\$252,250.19	4,681	\$773,375.25	14,461
Penicillin V Potassium	\$16,122.46	1,401	\$12,001.44	1,055	\$21,079.86	1,839	\$49,203.76	4,295
Ampicillin	\$1,631.21	129	\$877.11	83	\$1,678.84	147	\$4,187.16	359
Penicillin G Benzathine	\$2,072.57	43	\$721.87	17	\$1,883.83	32	\$4,678.27	92
Dicloxacillin	\$336.52	14	\$83.24	5	\$478.91	25	\$898.67	44
Piperacillin-tazobactam	\$4,745.33	4	\$562.70	1	\$1,718.49	2	\$7,026.52	7
Ampicillin-sulbactam	\$232.51	1			\$962.40	2	\$1,194.91	3
Nafcillin	\$2,123.19	2					\$2,123.19	2
Oxacillin	\$3,744.71	1	\$1,162.63	1			\$4,907.34	2
Benzodiazepines	\$56,050.56	7,148	\$44,728.92	5,708	\$79,631.96	10,790	\$632,564.59	49,264
Clonazepam	\$56,050.56	7,148	\$44,728.92	5,708	\$79,631.96	10,790	\$180,411.44	23,646
Lorazepam	\$47,912.49	7,245	\$38,558.91	5,838	\$60,874.56	9,057	\$147,345.96	22,140
Alprazolam	\$37,039.28	4,143	\$30,246.02	3,479	\$57,801.25	6,695	\$125,086.55	14,317
Diazepam	\$102,628.28	2,794	\$80,919.32	2,214	\$146,054.22	4,278	\$329,601.82	9,286
Temazepam	\$5,698.76	750	\$4,865.43	624	\$7,870.18	1,041	\$18,434.37	2,415
Clorazepate	\$2,182.48	202	\$1,908.24	173	\$3,352.43	294	\$7,443.15	669
Chlordiazepoxide	\$367.41	47	\$315.52	40	\$515.69	65	\$1,198.62	152
Triazolam	\$304.29	31	\$371.86	43	\$611.60	75	\$1,287.75	149

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Oxazepam	\$473.10	18	\$495.33	18	\$715.89	24	\$1,684.32	60
Antidepressants	\$416,144.82	11,449	\$340,082.08	9,291	\$749,983.23	20,751	\$1,506,210.13	41,491
Citalopram	\$17,132.58	2,201	\$13,551.07	1,704	\$27,242.15	3,657	\$57,925.80	7,562
Sertraline	\$11,605.58	1,506	\$10,157.91	1,321	\$19,229.40	2,590	\$40,992.89	5,417
Bupropion	\$129,515.26	1,572	\$102,767.14	1,238	\$204,251.98	2,472	\$436,534.38	5,282
Trazodone	\$9,385.25	1,143	\$7,767.72	958	\$19,813.82	2,467	\$36,966.79	4,568
Fluoxetine	\$18,555.82	1,232	\$15,126.39	991	\$29,343.77	2,132	\$63,025.98	4,355
Amitriptyline	\$3,670.58	706	\$2,815.64	537	\$7,091.77	1,370	\$13,577.99	2,613
Paroxetine	\$7,515.11	530	\$7,085.08	461	\$17,925.03	1,141	\$32,525.22	2,132
Mirtazapine	\$18,542.37	480	\$15,671.93	389	\$41,011.39	1,055	\$75,225.69	1,924
Desvenlafaxine	\$66,950.26	500	\$51,887.89	389	\$105,262.76	790	\$224,100.91	1,679
Venlafaxine	\$57,016.58	341	\$50,589.99	291	\$121,599.42	787	\$229,205.99	1,419
Doxepin	\$6,453.48	358	\$5,679.08	306	\$12,663.16	732	\$24,795.72	1,396
Escitalopram	\$18,693.43	183	\$16,046.24	150	\$34,012.38	310	\$68,752.05	643
Imipramine	\$6,755.76	208	\$4,534.22	153	\$7,388.37	264	\$18,678.35	625
Duloxetine	\$25,293.13	138	\$18,921.57	107	\$62,700.18	343	\$106,914.88	588
Nortriptyline	\$1,138.56	141	\$859.27	104	\$1,525.02	193	\$3,522.85	438
Fluvoxamine	\$6,606.91	76	\$6,775.52	68	\$12,551.41	149	\$25,933.84	293
Amitriptyline-perphenazine	\$2,784.23	67	\$2,468.64	58	\$6,465.16	151	\$11,718.03	276
Amitriptyline-chlordiazepoxide	\$1,425.73	28	\$1,465.87	26	\$2,595.67	49	\$5,487.27	103
Clomipramine	\$732.86	23	\$941.57	26	\$1,829.19	48	\$3,503.62	97

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Fluoxetine-olanzapine	\$6,203.08	11	\$4,803.71	9	\$14,146.34	25	\$25,153.13	45
Desipramine	\$78.88	2	\$76.25	2	\$792.17	13	\$947.30	17
Second Generation Antihistamines	\$397,701.80	15,710	\$279,578.42	11,160	\$351,937.79	13,806	\$1,029,218.01	40,676
Cetirizine	\$367,026.00	13,174	\$256,895.64	9,315	\$322,559.22	11,262	\$946,480.86	33,751
Loratadine	\$15,323.29	2,012	\$11,093.25	1,487	\$14,051.34	2,003	\$40,467.88	5,502
Cetirizine-pseudoephedrine	\$6,453.08	319	\$4,777.27	214	\$6,983.50	330	\$18,213.85	863
Loratadine-pseudoephedrine	\$2,003.42	113	\$1,116.25	68	\$2,259.53	129	\$5,379.20	310
Levocetirizine	\$4,758.37	65	\$4,259.57	52	\$3,794.04	49	\$12,811.98	166
Fexofenadine	\$1,061.82	18	\$763.53	18	\$1,560.15	27	\$3,385.50	63
Desloratadine	\$680.13	5	\$415.96	4	\$486.34	4	\$1,582.43	13
Fexofenadine-pseudoephedrine	\$338.75	3	\$256.95	2	\$243.67	2	\$839.37	7
Nonsteroidal Anti-inflammatory Agents	\$124,802.28	11,807	\$98,670.39	9,170	\$160,205.56	14,591	\$383,678.23	35,568
Ibuprofen	\$44,170.05	5,449	\$32,940.92	4,034	\$43,549.21	5,797	\$120,660.18	15,280
Naproxen	\$34,309.33	2,366	\$25,521.65	1,829	\$43,199.58	3,127	\$103,030.56	7,322
Aspirin	\$6,359.36	1,804	\$5,495.48	1,524	\$6,921.72	2,038	\$18,776.56	5,366
Meloxicam	\$7,454.12	1,103	\$6,109.50	894	\$12,998.34	1,893	\$26,561.96	3,890
Apap/butalbital/cafeine	\$23,884.18	918	\$17,829.31	738	\$33,464.42	1,341	\$75,177.91	2,997
Ketorolac	\$5,175.79	314	\$3,906.89	247	\$6,821.08	448	\$15,903.76	1,009
Diclofenac	\$9,024.57	307	\$7,682.59	243	\$12,692.98	449	\$29,400.14	999
Indomethacin	\$3,622.86	140	\$4,414.18	146	\$8,296.31	281	\$16,333.35	567
Etodolac	\$2,248.62	80	\$2,000.61	63	\$3,842.07	132	\$8,091.30	275

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claimst

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Oxaprozin	\$1,590.79	43	\$1,752.99	46	\$3,083.54	88	\$6,427.32	177
Celecoxib	\$6,952.99	42	\$5,791.40	35	\$12,556.15	79	\$25,300.54	156
Sulindac	\$960.11	42	\$639.60	28	\$1,388.75	59	\$2,988.46	129
Asa/butalbital/caffeine	\$738.97	27	\$732.51	24	\$1,699.13	68	\$3,170.61	119
Ketoprofen	\$479.11	29	\$357.56	19	\$739.70	57	\$1,576.37	105
Salsalate	\$246.62	8	\$195.49	7	\$373.73	11	\$815.84	26
Diflunisal	\$284.22	10	\$194.73	4	\$333.71	6	\$812.66	20
Fenoprofen	\$298.24	3	\$212.90	2	\$487.49	5	\$998.63	10
Diclofenac-misoprostol	\$83.69	1	\$341.23	2	\$424.92	3	\$849.84	6
Anticonvulsants, Miscellaneous	\$843,447.41	9,188	\$693,743.24	7,472	\$1,631,853.21	17,204	\$3,169,043.86	33,864
Gabapentin	\$72,786.44	1,941	\$60,103.07	1,590	\$150,359.30	3,747	\$283,248.81	7,278
Divalproex Sodium	\$160,768.93	1,539	\$130,276.77	1,230	\$329,041.23	3,120	\$620,086.93	5,889
Levetiracetam	\$99,217.18	1,149	\$84,233.61	944	\$182,837.71	2,068	\$366,288.50	4,161
Topiramate	\$52,604.27	1,008	\$37,751.27	761	\$97,891.30	1,757	\$188,246.84	3,526
Oxcarbazepine	\$119,819.64	934	\$97,371.73	759	\$246,620.37	1,722	\$463,811.74	3,415
Lamotrigine	\$73,156.95	852	\$57,071.04	683	\$119,296.76	1,475	\$249,524.75	3,010
Carbamazepine	\$35,827.67	561	\$33,683.46	501	\$73,551.84	1,190	\$143,062.97	2,252
Pregabalin	\$117,036.97	631	\$99,367.50	529	\$204,167.14	1,074	\$420,571.61	2,234
Zonisamide	\$10,320.45	221	\$7,889.88	187	\$22,249.18	456	\$40,459.51	864
Valproic Acid	\$9,857.83	198	\$7,318.40	148	\$14,852.96	294	\$32,029.19	640
Lacosamide	\$30,977.34	82	\$33,131.77	84	\$81,499.34	183	\$145,608.45	349

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Rufinamide	\$12,932.80	26	\$11,641.27	24	\$27,087.39	51	\$51,661.46	101
Felbamate	\$18,968.85	25	\$17,918.76	21	\$26,667.93	34	\$63,555.54	80
Tiagabine	\$5,341.44	10	\$4,552.59	9	\$12,839.29	23	\$22,733.32	42
Vigabatrin	\$23,556.78	5	\$11,432.12	2	\$42,891.47	10	\$77,880.37	17
Adrenals	\$1,268,632.29	13,034	\$903,826.58	9,137	\$1,129,305.55	11,615	\$3,301,764.42	33,786
Prednisolone	\$97,231.52	5,488	\$70,318.13	3,822	\$72,042.70	3,827	\$239,592.35	13,137
Budesonide	\$994,946.04	3,532	\$697,652.82	2,398	\$831,387.80	2,840	\$2,523,986.66	8,770
Prednisone	\$7,821.50	1,623	\$6,324.64	1,326	\$9,839.03	2,125	\$23,985.17	5,074
Methylprednisolone	\$7,846.67	769	\$3,422.75	346	\$9,062.24	881	\$20,331.66	1,996
Dexamethasone	\$5,862.39	422	\$4,675.75	326	\$6,618.85	443	\$17,156.99	1,191
Fluticasone	\$44,838.95	340	\$34,804.55	261	\$57,347.30	434	\$136,990.80	1,035
Budesonide-formoterol	\$48,221.08	234	\$41,023.13	200	\$76,158.65	369	\$165,402.86	803
Mometasone	\$34,938.46	266	\$24,516.37	182	\$30,015.53	229	\$89,470.36	677
Beclomethasone	\$15,623.68	139	\$12,296.31	103	\$19,884.37	168	\$47,804.36	410
Hydrocortisone	\$2,208.96	81	\$1,605.48	56	\$4,631.71	154	\$8,446.15	291
Fludrocortisone	\$1,646.26	63	\$1,150.79	46	\$1,915.04	73	\$4,712.09	182
Flunisolide Nasal	\$1,862.01	38	\$2,046.39	38	\$1,455.95	28	\$5,364.35	104
Formoterol-mometasone	\$5,474.82	26	\$3,850.82	19	\$8,866.40	34	\$18,192.04	79
Sulfonamides	\$136,412.34	10,580	\$107,092.50	8,372	\$173,275.45	13,509	\$416,780.29	32,461
Sulfamethoxazole-trimethoprim	\$135,680.80	10,540	\$106,436.24	8,334	\$170,211.36	13,386	\$412,328.40	32,260
Sulfasalazine	\$731.54	40	\$656.26	38	\$2,452.22	120	\$3,840.02	198

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claimst

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Sulfadiazine					\$611.87	3	\$611.87	3
Antipsychotics (atypical and typical)	\$2,599,294.37	8,200	\$2,103,432.95	6,651	\$5,727,077.27	16,982	\$10,429,804.59	31,833
Risperidone	\$291,811.90	2,620	\$245,658.79	2,164	\$748,501.37	5,427	\$1,285,972.06	10,211
Quetiapine	\$630,856.99	1,589	\$489,638.70	1,265	\$1,317,017.40	2,974	\$2,437,513.09	5,828
Aripiprazole	\$875,016.56	1,565	\$713,304.35	1,282	\$1,581,001.23	2,765	\$3,169,322.14	5,612
Olanzapine	\$372,420.79	532	\$279,582.20	389	\$824,858.05	1,103	\$1,476,861.04	2,024
Haloperidol	\$22,163.76	401	\$17,154.16	327	\$77,231.39	1,233	\$116,549.31	1,961
Ziprasidone	\$194,082.23	456	\$179,129.62	413	\$487,360.59	1,083	\$860,572.44	1,952
Chlorpromazine	\$8,800.96	264	\$6,524.38	234	\$14,453.16	512	\$29,778.50	1,010
Paliperidone	\$133,038.40	158	\$109,306.34	118	\$500,448.02	508	\$742,792.76	784
Prochlorperazine	\$2,482.38	168	\$1,479.80	96	\$3,732.92	216	\$7,695.10	480
Clozapine	\$20,415.86	116	\$17,110.82	95	\$45,013.59	262	\$82,540.27	473
Fluphenazine	\$3,688.81	71	\$2,767.09	52	\$12,871.23	266	\$19,327.13	389
Perphenazine	\$3,922.52	68	\$3,059.96	50	\$11,134.42	184	\$18,116.90	302
Asenapine	\$30,591.86	70	\$27,065.82	58	\$66,949.64	145	\$124,607.32	273
Thioridazine	\$1,046.62	35	\$1,027.31	35	\$2,713.82	82	\$4,787.75	152
Trifluoperazine	\$1,259.92	28	\$922.33	21	\$2,733.66	58	\$4,915.91	107
Thiothixene	\$636.02	26	\$270.65	15	\$1,577.80	64	\$2,484.47	105
Loxapine	\$1,248.84	16	\$1,350.54	16	\$4,146.85	49	\$6,746.23	81
Lurasidone	\$3,656.98	10	\$5,856.05	13	\$10,686.77	22	\$20,199.80	45
Iloperidone	\$1,973.68	4	\$1,997.90	5	\$14,347.12	25	\$18,318.70	34

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claimst

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Pimozide	\$179.29	3	\$226.14	3	\$298.24	4	\$703.67	10
Beta-Adrenergic Agonists	\$649,173.98	11,070	\$469,740.30	7,852	\$864,525.08	12,488	\$1,983,439.36	31,410
Albuterol	\$347,680.04	9,630	\$246,490.29	6,766	\$376,864.77	10,173	\$971,035.10	26,569
Fluticasone-salmeterol	\$244,559.12	1,117	\$183,720.46	847	\$380,180.69	1,702	\$808,460.27	3,666
Albuterol-ipratropium	\$40,891.41	207	\$30,648.08	156	\$86,791.80	434	\$158,331.29	797
Levalbuterol	\$11,635.80	51	\$5,786.03	35	\$14,743.32	75	\$32,165.15	161
Terbutaline	\$1,729.80	46	\$1,216.42	36	\$2,172.38	78	\$5,118.60	160
Formoterol	\$1,299.60	8	\$1,210.38	8	\$2,647.07	17	\$5,157.05	33
Pirbuterol	\$1,367.19	10	\$668.64	4	\$961.86	7	\$2,997.69	21
Contraceptives	\$549,424.50	10,743	\$428,921.05	8,617	\$523,941.61	10,865	\$1,502,287.16	30,225
Ethinyl Estradiol-norgestimate	\$131,926.48	3,625	\$97,040.88	2,920	\$114,531.26	3,643	\$343,498.62	10,188
Ethinyl Estradiol-norethindrone	\$204,487.06	3,308	\$158,501.50	2,626	\$191,907.40	3,278	\$554,895.96	9,212
Norethindrone	\$33,656.28	1,050	\$26,655.82	860	\$37,023.84	1,186	\$97,335.94	3,096
Ethinyl Estradiol-levonorgestrel	\$46,413.46	593	\$47,230.97	554	\$58,530.37	692	\$152,174.80	1,839
Ethinyl Estradiol-etonogestrel	\$41,436.62	593	\$31,201.82	443	\$42,210.24	594	\$114,848.68	1,630
Ethinyl Estradiol-norelgestromin	\$46,526.62	618	\$28,612.25	393	\$29,638.55	408	\$104,136.98	1,419
Ethinyl Estradiol-norgestrel	\$8,967.42	319	\$7,540.46	269	\$10,054.16	359	\$26,562.04	947
Drospirenone-ethinyl Estradiol	\$21,531.86	329	\$17,688.51	266	\$21,778.16	317	\$60,998.53	912
Desogestrel-ethinyl Estradiol	\$6,121.26	175	\$5,001.62	141	\$6,711.90	191	\$17,834.78	507
Drospirenone/ethinyl Estradiol/levom	\$5,389.12	69	\$7,047.64	91	\$8,305.60	106	\$20,742.36	266
Ethinyl Estradiol-ethynodiol	\$677.04	24	\$522.53	18	\$958.82	34	\$2,158.39	76

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Dienogest-estradiol	\$1,653.74	22	\$1,142.43	15	\$1,852.44	24	\$4,648.61	61
Levonorgestrel	\$413.54	10	\$435.16	12	\$599.88	16	\$1,448.58	38
Mestranol-norethindrone	\$224.00	8	\$299.46	9	\$479.43	17	\$1,002.89	34
Macrolides	\$373,762.22	12,009	\$258,514.90	8,302	\$290,221.95	9,724	\$922,499.07	30,035
Azithromycin	\$326,324.39	10,916	\$230,487.10	7,638	\$255,413.87	8,805	\$812,225.36	27,359
Clarithromycin	\$39,095.96	876	\$22,948.66	524	\$27,474.33	710	\$89,518.95	2,110
Erythromycin	\$7,435.86	185	\$4,537.17	123	\$6,729.97	189	\$18,703.00	497
Erythromycin-sulfisoxazole	\$906.01	32	\$541.97	17	\$603.78	20	\$2,051.76	69
Multivitamin Preparations	\$356,074.77	8,508	\$293,541.54	7,087	\$374,032.54	9,465	\$1,023,648.85	25,060
Multivitamin, Prenatal	\$345,893.10	7,692	\$286,515.90	6,490	\$364,569.10	8,564	\$996,978.10	22,746
Multivitamin With Iron	\$3,855.88	302	\$3,209.58	224	\$3,574.14	296	\$10,639.60	818
Multivitamin	\$2,934.35	191	\$2,023.80	153	\$1,742.36	249	\$6,700.51	593
Multivitamin With Fluoride	\$2,602.74	174	\$1,962.47	133	\$2,742.60	186	\$7,307.81	493
Multivitamin With Iron And Fluoride	\$2,141.62	122	\$1,161.92	70	\$2,360.80	128	\$5,664.34	320
Multivitamin With Minerals	\$286.46	27	\$221.93	21	\$532.30	42	\$1,040.69	90
Cephalosporins	\$586,281.09	9,655	\$411,497.48	6,863	\$459,419.58	8,440	\$1,457,198.15	24,958
Cefdinir	\$277,216.79	3,710	\$182,563.20	2,449	\$204,588.00	2,705	\$664,367.99	8,864
Cephalexin	\$42,060.09	2,766	\$34,061.51	2,178	\$45,646.32	3,247	\$121,767.92	8,191
Cefprozil	\$100,945.74	1,796	\$67,914.48	1,232	\$83,258.74	1,421	\$252,118.96	4,449
Cefixime	\$135,905.60	640	\$108,769.03	496	\$99,418.05	461	\$344,092.68	1,597

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Class Report
Top 15 Classes By Quarterly Number of Claims†

AHFS Class / Generic Molecule	April 2011		May 2011		June 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Cefuroxime	\$8,493.03	414	\$5,208.88	247	\$7,705.20	334	\$21,407.11	995
Cefadroxil	\$6,764.23	170	\$5,959.90	146	\$6,615.67	178	\$19,339.80	494
Ceftriaxone	\$7,456.98	132	\$4,814.15	100	\$10,406.27	70	\$22,677.40	302
Cefaclor	\$959.72	14	\$85.87	3	\$923.79	17	\$1,969.38	34
Cefepime	\$6,060.27	9	\$588.02	5	\$434.60	4	\$7,082.89	18
Cefpodoxime	\$161.97	3	\$210.52	4	\$169.99	2	\$542.48	9
Ceftazidime	\$256.67	1	\$1,321.92	3	\$252.95	1	\$1,831.54	5

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Molecule names accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Acetaminophen-hydrocodone	\$192,841.99	13,569	\$158,041.43	11,118	\$422,218.53	25,213	\$773,101.95	49,900
Acetaminophen-hydrocodone Bitartrate	\$192,833.42	13,567	\$157,854.69	11,115	\$422,129.18	25,207	\$772,810.29	49,888
Cetirizine	\$367,026.00	13,174	\$256,895.64	9,315	\$322,559.22	11,262	\$946,480.86	33,751
Cetirizine Hydrochloride	\$364,646.79	12,919	\$254,975.19	9,113	\$320,638.17	11,040	\$940,260.15	33,072
All Day Allergy	\$1,978.58	238	\$1,498.87	185	\$1,660.62	210	\$5,138.07	633
All Day Allergy Children's	\$400.63	17	\$421.58	17	\$260.43	12	\$1,082.64	46
Amoxicillin	\$129,468.99	13,044	\$87,523.65	8,994	\$100,693.82	10,803	\$317,686.46	32,841
Amoxicillin	\$126,050.35	13,011	\$85,999.14	8,978	\$99,093.10	10,787	\$311,142.59	32,776
Moxatag	\$3,418.64	33	\$1,524.51	16	\$1,600.72	16	\$6,543.87	65
Sulfamethoxazole-trimethoprim	\$135,680.80	10,540	\$106,436.24	8,334	\$170,211.36	13,386	\$412,328.40	32,260
Sulfamethoxazole-trimethoprim	\$95,779.94	6,060	\$73,877.92	4,640	\$113,535.60	6,966	\$283,193.46	17,666
Sulfamethoxazole-trimethoprim Ds	\$37,275.78	4,278	\$31,173.40	3,588	\$54,351.82	6,238	\$122,801.00	14,104
Smz-tmp Ds	\$851.38	106	\$540.42	62	\$1,000.12	116	\$2,391.92	284
Sulfatrim Pediatric	\$1,773.70	96	\$844.50	44	\$1,323.82	66	\$3,942.02	206
Azithromycin	\$326,324.39	10,916	\$230,487.10	7,638	\$255,413.87	8,805	\$812,225.36	27,359
Azithromycin	\$246,273.98	7,417	\$179,610.55	5,370	\$181,095.58	5,447	\$606,980.11	18,234
Azithromycin 5 Day Dose Pack	\$75,814.55	3,336	\$48,098.96	2,145	\$70,314.21	3,184	\$194,227.72	8,665

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Azithromycin 3 Day Dose Pack	\$3,987.73	158	\$2,777.59	123	\$3,964.33	173	\$10,729.65	454
Albuterol	\$347,680.04	9,630	\$246,490.29	6,766	\$376,864.77	10,173	\$971,035.10	26,569
Albuterol Sulfate	\$173,803.64	5,360	\$114,066.42	3,517	\$143,738.54	4,441	\$431,608.60	13,318
PDL Ventolin Hfa	\$172,461.47	4,157	\$131,836.69	3,202	\$232,506.63	5,704	\$536,804.79	13,063
Relion Ventolin Hfa	\$1,038.00	94	\$273.00	26	\$33.00	3	\$1,344.00	123
Clonazepam	\$56,050.56	7,148	\$44,728.92	5,708	\$79,631.96	10,790	\$180,411.44	23,646
Clonazepam	\$56,050.56	7,148	\$44,728.92	5,708	\$79,631.96	10,790	\$180,411.44	23,646
Multivitamin, Prenatal	\$345,893.10	7,692	\$286,515.90	6,490	\$364,569.10	8,564	\$996,978.10	22,746
Prenatal Plus	\$6,712.48	766	\$5,851.10	664	\$9,334.36	1,004	\$21,897.94	2,434
Neevo Dha	\$74,149.56	1,236	\$33,095.34	552	\$29,954.32	504	\$137,199.22	2,292
Neevodha	\$9,391.96	182	\$33,073.62	632	\$66,753.24	1,270	\$109,218.82	2,084
Rovin-nv Dha	\$31,333.80	716	\$31,045.98	710	\$27,479.66	628	\$89,859.44	2,054
Prenatal Plus	\$6,712.48	766	\$5,851.10	664	\$23.74	2	\$12,587.32	1,432
Neevo	\$24,962.82	478	\$16,202.86	308	\$17,137.60	328	\$58,303.28	1,114
Preque 10	\$18,805.20	396	\$13,214.76	276	\$17,684.34	376	\$49,704.30	1,048
Concept Dha	\$9,847.40	340	\$8,225.08	286	\$11,237.48	388	\$29,309.96	1,014
Prenate Essential	\$24,551.66	314	\$23,385.46	268	\$26,467.12	300	\$74,404.24	882
Prenexa With Dha	\$28,809.74	384	\$16,484.60	222	\$18,932.10	254	\$64,226.44	860
Nexa Select With Dha	\$11,575.80	154	\$15,942.48	212	\$19,790.80	264	\$47,309.08	630
Neevo	\$24,962.82	478	\$706.12	12	\$4,753.30	76	\$30,422.24	566
Taron-c Dha	\$4,380.72	168	\$3,284.20	128	\$5,514.92	212	\$13,179.84	508
Pnv-dha	\$8,753.04	166	\$6,845.80	132	\$7,769.38	150	\$23,368.22	448
Zatean-pn Plus	\$8,502.58	150	\$7,281.62	130	\$8,658.54	154	\$24,442.74	434

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Prenaplus	\$1,202.12	114	\$1,205.68	114	\$1,978.50	188	\$4,386.30	416
Pnv Select	\$6,609.84	144	\$5,112.88	112	\$6,809.86	148	\$18,532.58	404
Prenatal Ad	\$1,512.24	118	\$1,502.66	116	\$1,475.60	116	\$4,490.50	350
Concept Ob	\$3,612.94	134	\$2,597.88	96	\$3,143.58	118	\$9,354.40	348
Folcal Dha	\$4,577.00	90	\$5,976.04	118	\$6,102.64	120	\$16,655.68	328
Preferaob+dha	\$3,299.26	74	\$4,071.26	88	\$6,135.06	136	\$13,505.58	298
Vol-plus	\$948.30	82	\$966.32	84	\$1,489.08	130	\$3,403.70	296
Pnv- Iron	\$4,149.38	94	\$3,021.84	68	\$4,683.98	106	\$11,855.20	268
Prenate Elite Plus Iron	\$8,230.64	108	\$7,242.80	84	\$6,320.20	76	\$21,793.64	268
Preferaob	\$3,346.74	76	\$3,253.82	70	\$4,893.66	102	\$11,494.22	248
Gesticare Dha Dr	\$5,527.48	92	\$4,037.08	64	\$4,264.58	70	\$13,829.14	226
Prefera Ob-one	\$4,568.88	72	\$3,311.08	52	\$6,108.08	98	\$13,988.04	222
Paire Ob Plus Dha	\$2,654.46	70	\$2,372.92	62	\$3,477.16	90	\$8,504.54	222
Prenatabs Rx	\$865.12	74	\$690.48	56	\$993.22	86	\$2,548.82	216
Prenatal 19	\$694.28	48	\$1,198.54	84	\$1,129.92	82	\$3,022.74	214
Pnv-dha Plus Docusate	\$2,397.44	54	\$2,018.68	46	\$3,379.34	76	\$7,795.46	176
Natelle One Dha	\$5,003.12	56	\$3,994.16	44	\$4,270.60	46	\$13,267.88	146
Triveen Ten	\$775.54	22	\$1,238.92	38	\$2,775.40	86	\$4,789.86	146
Citranatal Assure	\$1,970.08	38	\$1,708.20	34	\$3,546.66	72	\$7,224.94	144
Rovin-nv	\$2,663.04	60	\$1,543.36	36	\$2,001.84	48	\$6,208.24	144
Folivan-ob	\$1,041.24	42	\$1,123.24	46	\$1,228.76	50	\$3,393.24	138
Se-natal 19	\$452.20	42	\$352.60	34	\$645.38	62	\$1,450.18	138
Zatean-pn Dha	\$1,906.14	36	\$1,233.30	24	\$3,834.34	70	\$6,973.78	130
Prenatal Plus Iron	\$337.92	36	\$226.66	24	\$277.36	34	\$841.94	94
Zatean-pn	\$1,669.46	36	\$937.90	22	\$1,587.94	36	\$4,195.30	94

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Citranatal Harmony	\$927.20	18	\$1,605.60	30	\$2,251.44	42	\$4,784.24	90
Prenate Plus	\$277.70	32	\$132.46	14	\$301.52	32	\$711.68	78
Tricare Dha One	\$1,091.52	20	\$1,043.60	20	\$1,490.96	28	\$3,626.08	68
Prenatal-u	\$304.74	24	\$152.64	12	\$318.72	26	\$776.10	62
Ob Natal One	\$592.40	16	\$898.94	26	\$517.60	14	\$2,008.94	56
Citranatal 90 Dha	\$628.38	14	\$827.12	18	\$1,200.74	24	\$2,656.24	56
Vemavite Prx 2	\$372.40	10	\$519.28	16	\$850.72	24	\$1,742.40	50
Taron-prx Plus Dha	\$791.60	20	\$717.84	18	\$476.92	12	\$1,986.36	50
Se-care	\$528.00	22	\$234.00	10	\$214.66	10	\$976.66	42
Citranatal Dha	\$594.48	14	\$371.96	10	\$688.38	18	\$1,654.82	42
Folcaps Omega 3	\$372.94	10	\$299.12	8	\$747.32	20	\$1,419.38	38
Prefera Ob Plus Dha	\$472.00	10	\$377.60	8	\$370.80	10	\$1,220.40	28
Cavan-heme Omega	\$578.92	16	\$322.24	8	\$82.06	2	\$983.22	26
Natelle One	\$1,119.16	14	\$313.76	4	\$319.76	4	\$1,752.68	22
Citranatal B-calm	\$186.54	6	\$246.90	6	\$456.80	10	\$890.24	22
Zatean-ch	\$132.64	4	\$331.60	10	\$265.28	8	\$729.52	22
Prenexa	\$353.60	8	\$442.00	10	\$88.40	2	\$884.00	20
Citranatal Rx	\$219.48	6	\$225.48	6	\$300.64	8	\$745.60	20
Gesticare	\$500.00	10	\$94.00	2	\$294.00	6	\$888.00	18
Vinate Care	\$427.58	14			\$117.88	4	\$545.46	18
Ultimatecare One	\$149.60	4	\$222.98	8	\$143.96	4	\$516.54	16
Duet Dha Balanced	\$203.60	4	\$435.04	8	\$214.52	4	\$853.16	16
Pnv-dha Plus	\$89.30	2	\$357.20	8	\$178.60	4	\$625.10	14
Triveen-prx Rnf	\$89.90	2	\$179.80	4	\$269.70	6	\$539.40	12
TI-select					\$546.80	8	\$546.80	8

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Medroxyprogesterone	\$229,731.84	7,281	\$199,148.10	6,438	\$280,684.89	8,838	\$709,564.83	22,557
Medroxyprogesterone Acetate	\$170,694.42	4,032	\$140,446.83	3,309	\$209,832.24	4,998	\$520,973.49	12,339
Depo-subq Provera 104	\$59,037.42	3,249	\$58,434.06	3,126	\$70,852.65	3,840	\$188,324.13	10,215
Montelukast	\$1,179,106.27	8,264	\$842,817.71	5,906	\$1,142,366.32	7,991	\$3,164,290.30	22,161
PDL Singulair	\$1,179,106.27	8,264	\$842,817.71	5,906	\$1,142,366.32	7,991	\$3,164,290.30	22,161
Lorazepam	\$47,912.49	7,245	\$38,558.91	5,838	\$60,874.56	9,057	\$147,345.96	22,140
Lorazepam	\$47,912.49	7,245	\$38,558.91	5,838	\$60,874.56	9,057	\$147,345.96	22,140
Promethazine	\$70,948.58	6,146	\$53,533.20	4,556	\$94,815.30	7,758	\$219,297.08	18,460
Promethazine Hydrochloride	\$64,432.84	5,698	\$48,502.84	4,212	\$86,333.68	7,206	\$199,269.36	17,116
Phenadoz	\$4,337.96	334	\$3,024.58	228	\$4,500.12	336	\$11,862.66	898
Promethegan	\$2,177.78	114	\$2,005.78	116	\$3,981.50	216	\$8,165.06	446
Diphenhydramine	\$25,478.32	5,420	\$22,348.76	4,760	\$29,288.32	6,468	\$77,115.40	16,648
Q-dryl	\$14,851.04	3,052	\$13,720.28	2,820	\$16,310.80	3,396	\$44,882.12	9,268
Diphenhydramine Hydrochloride	\$5,152.12	1,176	\$4,438.60	1,056	\$7,488.56	1,852	\$17,079.28	4,084
Banophen	\$1,971.88	472	\$1,532.04	348	\$2,592.68	612	\$6,096.60	1,432
Diphenhist	\$2,209.44	460	\$1,901.16	380	\$2,021.20	424	\$6,131.80	1,264
Hydramine	\$548.28	116	\$376.32	80	\$285.52	64	\$1,210.12	260
Diphedryl	\$297.44	56	\$211.32	40	\$157.44	32	\$666.20	128
Child Allergy	\$324.32	60	\$66.60	12	\$155.36	28	\$546.28	100

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Hydroxyzine	\$81,430.00	4,814	\$69,651.40	4,066	\$128,920.20	7,378	\$280,001.60	16,258
Hydroxyzine Hydrochloride	\$67,100.44	3,370	\$57,846.28	2,876	\$100,317.88	4,624	\$225,264.60	10,870
Hydroxyzine Pamoate	\$14,329.56	1,444	\$11,805.12	1,190	\$28,602.32	2,754	\$54,737.00	5,388
Ibuprofen	\$44,170.05	5,449	\$32,940.92	4,034	\$43,549.21	5,797	\$120,660.18	15,280
Ibuprofen	\$39,237.11	4,617	\$29,360.38	3,441	\$37,285.61	4,678	\$105,883.10	12,736
Ibu	\$4,156.70	744	\$3,092.07	539	\$5,599.43	1,042	\$12,848.20	2,325
Ibuprofen Childrens	\$704.94	80	\$444.98	48	\$586.96	67	\$1,736.88	195
Amoxicillin-clavulanate	\$312,455.64	5,840	\$208,669.42	3,940	\$252,250.19	4,681	\$773,375.25	14,461
Amoxicillin-clavulanate	\$304,216.32	5,746	\$204,778.73	3,887	\$247,876.87	4,631	\$756,871.92	14,264
PDL Augmentin	\$7,035.64	80	\$3,790.56	50	\$3,550.82	41	\$13,909.21	168
Amoxicillin-clavulanate Er	\$953.47	11	\$502.06	8	\$2,012.70	22	\$3,405.13	40
Alprazolam	\$37,039.28	4,143	\$30,246.02	3,479	\$57,801.25	6,695	\$125,086.55	14,317
Alprazolam	\$29,865.61	4,069	\$24,589.75	3,422	\$50,895.33	6,624	\$105,350.69	14,115
Alprazolam Er	\$7,173.67	74	\$5,656.27	57	\$6,905.92	71	\$19,735.86	202
Prednisolone	\$97,231.52	5,488	\$70,318.13	3,822	\$72,042.70	3,827	\$239,592.35	13,137
Prednisolone Sodium Phosphate	\$29,565.72	2,243	\$18,661.61	1,550	\$18,897.34	1,544	\$67,124.67	5,337
Prednisolone	\$25,475.58	1,888	\$17,195.25	1,281	\$20,007.38	1,425	\$62,678.21	4,594
Veripred 20	\$29,387.54	1,183	\$20,726.53	820	\$18,680.98	703	\$68,795.05	2,706
Orapred Odt	\$11,862.12	125	\$13,086.10	139	\$13,866.34	130	\$38,814.56	394
Millipred	\$847.60	45	\$600.66	30	\$523.19	22	\$1,971.45	97

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Metronidazole	\$23,435.50	3,660	\$18,540.50	2,924	\$28,965.02	4,656	\$70,941.02	11,240
Metronidazole	\$23,435.50	3,660	\$18,540.50	2,924	\$28,965.02	4,656	\$70,941.02	11,240
Omeprazole	\$158,179.30	2,875	\$134,328.08	2,344	\$320,774.48	5,680	\$613,281.86	10,899
Omeprazole	\$158,179.30	2,875	\$133,951.90	2,342	\$320,774.48	5,680	\$612,905.68	10,897
Amphetamine-dextroamphetamine	\$566,863.24	3,581	\$416,102.04	2,625	\$680,713.56	4,160	\$1,663,678.84	10,366
PDL Adderall Xr	\$480,233.48	2,209	\$349,330.29	1,600	\$584,608.68	2,639	\$1,414,172.45	6,448
Amphetamine-dextroamphetamine	\$56,439.78	1,195	\$42,043.35	882	\$64,750.81	1,338	\$163,233.94	3,415
Amphetamine-dextroamphetamine Er	\$29,862.53	176	\$24,728.40	143	\$31,354.07	183	\$85,945.00	502
Risperidone	\$291,811.90	2,620	\$245,658.79	2,164	\$748,501.37	5,427	\$1,285,972.06	10,211
Risperidone	\$241,395.46	2,559	\$199,674.92	2,108	\$526,112.33	5,160	\$967,182.71	9,827
Risperdal Consta	\$50,416.44	61	\$45,983.87	56	\$220,473.14	263	\$316,873.45	380
Risperdal					\$854.44	2	\$854.44	2
Risperdal M-tab					\$1,061.46	2	\$1,061.46	2
Ethinyl Estradiol-norgestimate	\$131,926.48	3,625	\$97,040.88	2,920	\$114,531.26	3,643	\$343,498.62	10,188
Tri-sprintec	\$21,949.89	932	\$16,689.40	748	\$22,999.27	1,025	\$61,638.56	2,705
Ortho Tri-cyclen Lo	\$60,791.35	918	\$35,955.46	608	\$33,792.09	603	\$130,538.90	2,129
Trinessa	\$19,237.17	628	\$18,069.05	567	\$23,488.87	726	\$60,795.09	1,921
Sprintec	\$8,047.13	410	\$6,245.52	320	\$8,418.73	433	\$22,711.38	1,163
Ortho Tri-cyclen Lo	\$11,252.62	137	\$24,637.05	299	\$39,768.28	483	\$75,657.95	919
Ortho Tri-cyclen	\$6,122.30	204	\$6,665.83	225	\$8,291.55	294	\$21,079.68	723
Mononessa	\$5,534.22	190	\$4,495.55	153	\$6,284.80	214	\$16,314.57	557

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Resource Utilization Report
Drug Detail Report
Top 25 Drugs By Quarterly Number of Claims†

Generic Molecule / Drug Name	May 2011		June 2011		July 2011		Quarter	
	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims	Total Paid*	Total Claims
Tri-previfem	\$6,028.76	182	\$5,106.54	148	\$7,074.43	194	\$18,209.73	524
Ortho-cyclen	\$2,548.27	107	\$2,233.66	100	\$2,446.39	98	\$7,228.32	305
Previfem	\$1,667.39	54	\$1,579.87	51	\$1,735.13	56	\$4,982.39	161
Methylphenidate	\$609,669.13	3,451	\$431,938.85	2,529	\$719,820.16	4,090	\$1,761,428.14	10,070
PDL Concerta	\$510,903.97	2,557	\$287,422.77	1,447	\$575,207.39	2,839	\$1,373,534.13	6,843
PDL Metadate Cd	\$49,268.15	307	\$35,621.18	223	\$62,748.21	385	\$147,637.54	915
PDL Methylin	\$8,998.84	182	\$6,423.44	144	\$10,625.36	244	\$26,047.64	570
Methylphenidate Hydrochloride	\$4,999.00	183	\$3,342.54	145	\$6,285.32	219	\$14,626.86	547
Methylphenidate Hydrochloride Er			\$75,039.64	421	\$22,098.60	124	\$97,138.24	545
PDL Daytrana	\$30,075.56	176	\$21,168.33	122	\$36,861.76	214	\$88,105.65	512
Ritalin La	\$4,840.88	30	\$2,525.92	16	\$5,186.27	36	\$12,553.07	82
Methylphenidate Hydrochloride Sr	\$502.63	13	\$299.23	9	\$467.67	18	\$1,269.53	40
Methylin Er	\$80.10	3	\$95.80	2	\$339.58	11	\$515.48	16
Acetaminophen-codeine	\$26,526.31	3,198	\$19,781.56	2,404	\$33,435.29	3,932	\$79,743.16	9,534
Acetaminophen-codeine Phosphate	\$26,526.31	3,198	\$19,781.56	2,404	\$33,421.23	3,931	\$79,729.10	9,533

* Dollar figures represent reimbursement to pharmacies and are not representative of overall Medicaid costs.

† Drugs accounting for less than \$500 in quarterly amount paid are not shown

Prepared by the Evidence-Based DUR Initiative, MS-DUR

Overview of Medical and POS Billings

Background

DOM needs to better understand what drugs are billing billed through medical and POS claims in order to determine if policy changes need to be made in order to better control and monitor use of expensive medications. Many providers are moving away from “buy-and-bill” for expensive medications which shifts these claims to specialty pharmacies or possibly “brown-bagging” through community pharmacies. This initial analysis is to provide an overview of what drugs are billed through both types of claims and the trend in billing as medical and POS.

Analysis

Medical and POS claims from January 1, 2010 – June 30, 2011 were analyzed. All J-code billings during the date range for an amount of \$100 or more were extracted. All POS claims for drugs with NDCs corresponding to these J-codes were extracted. Initial analysis was to examine number of claims through medical and POS and average claim cost to identify potential target drugs for further analysis.

Preliminary Results

Of the drugs with claims submitted through both medical and POS during the observation period, 76 were identified as being predominately billed through POS or with a mix of billing through both systems. These products and their claims during the observation period are summarized in the following table.

MEDICATIONS BILLED PRIMARILY THROUGH POS OR BOTH															
J Code - generic name		2010 Q1		2010 Q2		2010 Q3		2010 Q4		2011 Q1		2011 Q2		Average Medical \$/claim*	Average POS \$/claim*
		claim s	% Medical	claim s	% Medical	claim s	% Medical	claim s	% Medical	claim s	% Medical	claim s	% Medical		
J7198	Antithrombin Coagulant Complex	27	0.0%	18	0.0%	33	0.0%	24	0.0%	19	0.0%	24	0.0%	-	\$71,978
J7192	Antithrombin Factor (Recombinant)	75	0.1%	41	0.0%	54	0.0%	43	0.0%	15	0.0%	14	0.0%	\$1,350	\$17,290
J1566	Immune Globulin (Human) IV	44	0.3%	25	0.1%	47	0.3%	51	0.3%	5	0.0%	10	0.1%	\$2,113	\$9,891
J9264	Paclitaxel Protein-Bound Particles	5	100.0%	8	100.0%	13	0.1%	9	0.1%	16	0.2%	14	0.1%	\$2,353	\$8,868
J9355	Trastuzumab	215	2.7%	225	1.8%	238	100.0%	167	2.6%	164	100.0%	128	100.0%	\$1,822	\$8,315
J9263	Oxaliplatin	159	100.0%	152	100.0%	154	100.0%	160	2.5%	150	100.0%	127	100.0%	\$2,733	\$6,217
J9035	Bevacizumab	218	3.0%	210	100.0%	252	4.5%	236	4.1%	184	2.9%	140	2.6%	\$3,213	\$5,405
J0878	Daptomycin	52	0.7%	91	2.2%	138	2.9%	55	0.8%	38	0.6%	51	0.7%	\$242	\$3,712
J1745	Infliximab	78	100.0%	81	100.0%	89	100.0%	74	100.0%	22	0.5%	17	0.5%	\$2,447	\$3,248
J2323	Natalizumab	31	0.5%	32	0.8%	49	0.8%	40	0.5%	19	0.0%	19	0.0%	\$2,311	\$3,198
J2353	Octreotide Acetate	17	0.6%	16	0.6%	20	0.7%	29	0.7%	17	0.4%	10	0.3%	\$3,062	\$2,757
J1440, J1441	Filgrastim	175	26.5%	144	22.8%	170	20.4%	212	23.5%	128	19.4%	132	23.2%	\$294	\$2,949
J8700	Temozolomide	44	0.0%	31	0.0%	36	0.0%	34	0.0%	26	0.0%	18	0.0%	-	\$2,909
J2505	Pegfilgrastim	218	7.2%	201	7.9%	264	8.1%	231	7.3%	165	5.1%	122	4.2%	\$2,178	\$2,744
J0585	OnabotulinumtoxinA	129	100.0%	110	5.0%	134	7.4%	106	3.1%	63	100.0%	67	100.0%	\$1,205	\$2,221
J0770	Colistimethate Sodium	15	0.0%	8	0.0%	3	0.0%	4	0.0%	3	0.1%	7	0.0%	-	\$1,776
J9214	Interferon Alfa-2B	15	0.3%	10	0.5%	47	2.3%	33	3.6%	1	0.0%	2	0.0%	\$415	\$1,635
J0881	Darbepoetin Alfa-Polysorbate 80	150	6.9%	116	6.5%	100	5.2%	105	5.1%	66	2.4%	52	2.7%	\$612	\$1,628
J3243	Tigecycline	4	0.2%	20	0.4%	14	0.4%	9	0.3%	7	0.2%	9	0.3%	\$134	\$1,564
J2820	Sargramostim	122	8.3%	158	10.6%	142	5.7%	105	100.0%	45	100.0%	65	6.3%	\$244	\$1,450
J2185	Meropenem	17	0.0%	4	0.0%	4	0.0%	11	0.0%	7	0.1%	3	0.0%	-	\$1,370
J0885, J0886	Epoetin Alfa	587	58.6%	563	65.5%	640	65.3%	452	61.9%	106	4.2%	146	6.6%	\$471	\$1,361
J3488, J3487	Zoledronic Acid	111	100.0%	123	17.6%	177	9.6%	159	9.2%	103	9.9%	54	100.0%	\$911	\$1,322
J1650	Enoxaparin Sodium	528	1.2%	356	1.5%	391	2.4%	357	1.4%	293	1.4%	287	1.1%	\$153	\$1,302
J9217, J1950	Leuprolide Acetate	190	1.6%	132	1.2%	163	1.1%	178	1.9%	146	0.5%	143	0.8%	\$1,138	\$1,237
J8705, J9350	Topotecan HCl	74	100.0%	54	100.0%	59	100.0%	75	100.0%	26	92.3%	1	0.0%	\$1,049	\$1,066
J9395	Fulvestrant	16	1.5%	14	100.0%	13	1.4%	4	100.0%	15	100.0%	15	1.5%	\$918	\$863
J0743	Imipenem-Cilastatin	18	0.0%	8	0.0%	7	0.2%	4	0.0%	14	0.2%	5	0.1%	\$138	\$914
J0475	Baclofen	78	9.1%	56	5.9%	70	6.9%	60	5.1%	35	3.5%	29	2.4%	\$877	\$771
J2794	Risperidone Microspheres	592	0.0%	445	0.1%	541	0.1%	488	0.0%	282	0.0%	274	0.0%	-	\$812
J1652	Fondaparinux Sodium	24	0.4%	14	0.1%	23	1.5%	28	0.6%	9	0.1%	19	0.3%	\$134	\$800
J1335	Ertapenem Sodium	27	2.2%	22	0.0%	22	0.5%	23	0.5%	18	0.5%	11	0.0%	\$140	\$722
J7506	Prednisone	5672	39.3%	3676	0.0%	4592	0.0%	5400	0.0%	4115	0.0%	4700	0.0%	\$698	\$5
J2543	Piperacillin Sodium-Tazobactam Sodium	15	0.3%	13	0.3%	27	0.5%	67	0.7%	9	1.2%	16	0.2%	\$147	\$670
J9178	Epirubicin HCl	2	100.0%	1	100.0%	4	100.0%	4	0.7%	7	1.3%	7	100.0%	\$595	-
J9390	Vinorelbine Tartrate	5	100.0%	6	1.0%	7	1.0%	27	100.0%	32	100.0%	6	100.0%	\$361	\$519
J1956	Levofloxacin	22	0.8%	8	0.9%	16	0.6%	5	0.2%	7	1.0%	13	1.0%	\$490	\$326
J0692	Cefepime HCl	19	0.0%	13	0.7%	22	0.4%	23	0.0%	14	0.0%	14	0.0%	\$271	\$487
J1642, J1644, J7040	Heparin Sodium (Porcine)	144	3.5%	144	12.1%	124	0.5%	143	1.6%	166	23.5%	155	20.2%	\$483	\$271
J1200	Diphenhydramine HCl	11	7.4%	9	9.4%	33	35.7%	27	61.5%	11	36.3%	12	19.7%	\$423	\$14
J2920, J2930	Methylprednisolone Sod Succ	37	4.8%	20	2.6%	25	4.9%	22	12.3%	17	2.2%	18	0.0%	\$415	\$50
J8501	Aprepitant	70	9.8%	34	4.0%	33	4.3%	44	4.2%	24	4.2%	30	4.1%	\$229	\$330
J1100	Dexamethasone Sodium Phosphate	142	40.8%	86	43.2%	77	79.7%	109	17.3%	74	19.0%	35	12.2%	\$323	\$5
J0295	Ampicillin & Sulbactam Sodium	8	0.0%	9	1.0%	16	0.4%	10	0.0%	1	100.0%	10	1.0%	\$151	\$315
J7502	Cyclosporine	90	0.0%	58	0.0%	70	1.0%	61	0.7%	44	0.3%	37	0.0%	\$302	\$308

August 18, 2011

J Code - generic name	2010 Q1		2010 Q2		2010 Q3		2010 Q4		2011 Q1		2011 Q2		Average Medical \$/claim*	Average POS \$/claim*
	Total claim	% Medical	Total claim	% Medical	Total claim	% Medical	Total claim	% Medical	Total claim	% Medical	Total claim	% Medical		
J1750 Iron Dextran	15	100.0%	25	4.1%	38	7.4%	29	48.9%	20	36.7%	8	100.0%	\$290	\$254
J3370 Vancomycin HCl	187	1.6%	125	9.7%	119	3.3%	132	6.7%	62	2.5%	51	0.5%	\$173	\$289
J3030 Sumatriptan Succinate	31	0.7%	20	0.0%	29	1.5%	32	1.0%	23	0.4%	21	0.0%	\$122	\$285
J9181 Etoposide	30	100.0%	29	100.0%	20	100.0%	32	100.0%	24	100.0%	10	11.9%	\$278	-
J2405 Ondansetron HCl	325	66.9%	303	83.4%	378	46.7%	433	88.1%	377	90.3%	274	85.9%	\$262	\$125
J1815 Insulin Regular (Human)	7647	0.6%	5443	2.5%	6997	1.9%	7030	1.2%	5361	1.8%	5394	0.0%	\$259	\$162
J0690 Cefazolin Sodium	10	57.9%	7	7.5%	16	5.4%	26	6.9%	9	1.7%	18	100.0%	\$222	\$157
J1055 Medroxyprogesterone Acetate (Contraceptive)	7199	0.0%	5082	3.2%	6996	2.9%	7034	8.0%	6419	2.7%	5881	0.0%	\$211	\$34
J0713 Cefazidime	10	0.4%	10	0.0%	19	0.9%	13	0.0%	8	0.0%	5	0.0%	-	\$202
J0170 Epinephrine	670	3.3%	626	5.0%	1192	1.7%	696	2.3%	576	0.0%	792	0.0%	\$201	\$124
J2270, J2271 Morphine Sulfate	16	62.5%	18	24.9%	13	76.9%	9	7.5%	8	12.7%	17	5.0%	\$198	\$44
J9370, J9375 Vincristine Sulfate	3	100.0%	8	29.1%	15	60.9%	10	63.1%	5	100.0%	6	100.0%	\$193	\$26
J2175 Meperidine HCl	7	31.6%	9	19.9%	10	40.3%	4	39.8%	8	9.8%	13	23.3%	\$191	\$14
J3420 Cyanocobalamin	1695	0.0%	1228	17.3%	1852	29.6%	1838	0.0%	1708	0.0%	1320	0.0%	\$177	\$5
J0702 Betamethasone Acetate & Sod Phosphate	5	100.0%	25	38.1%	12	18.0%	29	31.1%	6	9.6%	6	10.3%	\$175	\$35
J2550 Promethazine HCl	138	0.0%	60	2.8%	68	3.2%	82	4.0%	73	14.6%	53	14.8%	\$169	\$23
J2250 Midazolam HCl	2	100.0%	10	100.0%	24	100.0%	8	55.6%	11	100.0%	12	100.0%	\$166	-
J1610 Glucagon (rDNA)	220	1.3%	119	2.5%	156	1.9%	128	1.9%	160	3.9%	141	3.7%	\$156	\$161
J2001 Lidocaine HCl (Cardiac)	50	26.1%	33	31.3%	44	46.8%	37	34.8%	40	0.0%	44	27.0%	\$154	\$6
J0744 Ciprofloxacin	25	3.0%	7	0.5%	19	100.0%	14	3.9%	2	100.0%	5	100.0%	\$152	\$136
J9190 Fluorouracil	33	56.1%	13	21.3%	27	33.7%	26	29.4%	19	13.8%	16	13.1%	\$147	\$61
J7060 Dextrose	18	0.0%	16	0.0%	13	6.6%	15	7.0%	9	6.4%	6	0.0%	\$146	\$14
J2060 Lorazepam	508	29.6%	385	30.8%	462	31.2%	460	36.7%	429	0.0%	381	0.0%	\$144	\$7
J9250 Methotrexate Sodium	52	23.0%	40	0.0%	50	0.0%	76	6.7%	45	0.0%	48	7.5%	\$143	\$13
J0696 Ceftriaxone Sodium	742	76.6%	452	64.3%	551	76.6%	840	84.9%	612	80.3%	517	74.7%	\$139	\$70
J9070, J9090 J9092, J9093 J9096 Cyclophosphamide	24	100.0%	28	100.0%	50	100.0%	45	93.3%	38	97.4%	48	100.0%	\$136	-
J3105 Terbutaline Sulfate	8	6.0%	13	100.0%	10	8.3%	6	100.0%	8	100.0%	7	100.0%	\$129	\$85
J0570 Penicillin G Benzathine	155	14.4%	62	2.0%	71	7.4%	188	7.9%	138	2.1%	91	0.0%	\$121	\$46
J1030, J1040 Methylprednisolone Acetate	13	0.0%	12	13.6%	9	12.1%	15	0.0%	16	7.7%	10	0.0%	\$121	\$14
J7608 Acetylcysteine	51	0.0%	28	0.0%	45	3.2%	31	0.0%	20	0.0%	12	0.0%	-	\$33

NOTE: Only includes products with more than 10 claims in 2010 or first half of 2011 and medical billing charges of \$100+

* Average cost/claim only computed if 3 or more claims for product

Next Action:

Analysis is on-going. MS-DUR will conduct further analyses by route of administration, and therapeutic area to identify potential drugs for recommended DUR Board action.

DUR Board action at this time – Seeking comments and recommendations.

High Dose Abilify® (aripiprazole) Prescribing

Background/Issue:

The Division of Medicaid needs to evaluate whether the use of high doses of Abilify® (>30mg/day) is a significant problem that needs to be addressed through clinical edits and what the impact of the edits might be on providers and the prior authorization process.

Analysis:

Need to determine the following:

- How often do prescriptions for Abilify® exceed the recommended maximum dose?
- Length of time (months) that patients remain on high dose Abilify® when it does occur?
- How many prescribers / pharmacies are involved in high dose Abilify® prescriptions?

Preliminary Results:

During the period January 1, 2010 – June 30, 2011, a total of 1,396 beneficiaries were dispensed Abilify® prescriptions for daily doses exceeding 30mg/day.

Abilify dose	# of Benes	# RXs	Average # fills
Any dose	6,661		
<= 30mg/day	6,100	28,477	4.7
> 30mg/day	1,396	5,123	3.7

Most beneficiaries (79%) only filled Abilify® prescriptions for <=30 mg/day. Of the beneficiaries filling prescriptions for Abilify® daily doses > 30mg, most were filling Abilify® prescriptions for both dosages.

# of Benes	% of Benes	Dose Taken
5,264	79%	<= 30mg only
836	13%	both doses
560	8%	> 30mg only

Prescription fill patterns for patients taking high dosages indicate a variety of treatment patterns may exist with respect to use of high dose Abilify® including:

- beneficiaries only being treated with the high dose of Abilify®,
- starting with lower doses and titrating up,
- starting with high dose and titrating down,
- and intermixing low and high dose prescriptions.

# of Benes	% of Benes	Pattern When Filling Prescriptions for Both Dosages
560	40%	No use of both dosages
199	14%	Low dose followed by high dose
305	22%	High dose followed by low dose
332	24%	Low and high doses intermixed

Use of high dose Abilify® does not appear to be limited to certain providers or geographic areas. High dose prescriptions were written by 422 different providers and filled in 485 different pharmacies.

Next Actions:

Based on the treatment patterns observed, further analysis would appear to be warranted before any high dose edits are recommended. Additional analyses planned include:

- examine use of high dose by diagnosis;
- breakdown by route of administration and therapeutic categories;
- examine use of high dose by type of prescriber (specialist, PCP, NP, etc.);
- examine whether hospitalization or ED visits for condition occur before use of high doses;
- determine typical number of days of therapy authorized by prescriptions for high doses.

DUR Board action at this time – Seeking comments and recommendations.

Mental Health Treatment in Pediatric Beneficiaries

Background/Issue:

Since children represent the majority of Medicaid beneficiaries and the treatment of mental health issues in this population is of particular interest, the Mississippi Division of Medicaid has asked MS-DUR to conduct a fairly comprehensive evaluation of mental treatment within this population. The primary goal is to evaluate the quality of mental health care being provided and to identify any clinical edits or other policy changes that may be warranted to assure the best treatment possible is being provided to this population.

Proposed analysis:

This will be a fairly thorough evaluation of mental health treatment among children (up to age 21) covered by the DOM. Specific issues to be examined include:

- What is the prevalence of major mental health diagnoses in this population (ADD, schizophrenia, bi-polar, depression, anxiety, autism, etc.)?
- What mental health drugs are being used in this population to treat these conditions?
- What variations exist in treatment patterns exist by eligibility categories (especially foster kids), race, and age?
- What variations exist in treatment patterns by prescriber and geographic locations? Identify and characterize outliers.
- What is the incidence of suicide among Medicaid kids and how does this differ for kids with and without mental health diagnoses, eligibility category, etc.?

Depending on the results, this analysis may be expanded to overview the prevalence of all disease states and treatment patterns in this population.

Preliminary Results:

At this time MS-DUR is in the process of obtaining the files needed to develop a comprehensive beneficiary eligibility file that can be used to determine precise denominators for prevalence estimates and for classifying children based on reason for eligibility.

Preliminary prevalence estimates are reported today in order to give the DUR Board an idea of the number of children that may be receiving treatment for mental health conditions.

CAUTION should be exercised with respect to the estimated prevalence of each condition since the denominator for these estimates at this time are based on all children having at least one medical or pharmacy claim submitted during the data analysis period. Once full eligibility information is available, these estimates will change due to the inclusion of healthy children that are enrolled in Medicaid but did not have any claims during this period.

As shown in Table 1, children 5 and under represent 41% of the children enrolled in Medicaid. Based on these preliminary estimates, the 12-17 year olds have the highest prevalence of a

mental health diagnosis (20%), while the 5 and under age group has the lowest prevalence of a mental health diagnosis (3.8%). The prevalence of different diagnoses varies by age group. As would be expected, ADD is highest among the 6-11 year olds and 12-17 year olds. The prevalence of depression, anxiety, and schizophrenia increases with age.

Table 1: Prevalence of Mental Health Diagnoses by Age Group

Age⇒	All		< 5 years		6-11 years		12-17 years		18-21 years	
POPULATION	432,654	100%	177,987	41.14%	115,456	26.69%	93,609	21.64%	45,602	10.54%
Diag↓	Count	% prev.	Count	% age % diag	Count	% age % diag.	Count	% age % diag	Count	% age % diag
Any MH Diag	51,460	11.89	6,776	3.81 13.17	19,928	17.26 38.73	18,757	20.04 36.45	5,999	13.16 11.66
ADD	29,047	7.93	1,924	1.08 6.62	15,301	13.25 52.68	10,334	11.04 35.58	1,488	3.26 5.12
Bipolar	6,701	1.55	144	0.08 2.15	1,567	1.36 23.38	3,712	3.97 55.39	1,278	2.80 19.07
Depression	7,088	1.64	50	0.03 0.71	908	0.79 12.81	3,816	4.08 53.84	2,314	5.07 32.56
Anxiety	8,661	2.00	2,547	1.43 29.41	2,127	1.84 24.56	2,425	2.59 28.00	1,562	3.43 18.03
Schizophrenia	1,715	0.40	34	0.02 1.98	290	0.25 16.91	730	0.78 42.57	661	1.45 38.54
Conduct	8,486	1.96	1,572	0.88 18.52	3,512	3.04 41.39	2,962	3.16 34.90	440	0.96 5.19
ODD	10,645	2.46	417	0.23 3.92	3,546	3.07 33.31	5,810	6.21 54.58	872	1.91 8.19
Learning	2,755	0.64	1,201	0.67 43.59	936	0.81 33.97	512	0.55 18.58	106	0.23 3.85
Autism	1,417	0.33	332	0.19 23.43	608	0.53 42.91	334	0.36 23.57	143	0.31 10.09

NOTE: a = Prevalence of diagnosis (denominator = beneficiaries ≤ 21 years on 12/31/2010 with a medical or prescription claim, N = 432,654); b = Prevalence of diagnosis (denominator = beneficiaries in the age group)

Table 2 shows the prevalence of mental health diagnoses by gender and race. Preliminary results show that males may be more likely than females to have diagnoses of bipolar, conduct disorder, opposition defiant disorder, learning disability, and autism. Females are more likely to be diagnosed with depression. Whites were more likely than blacks to be diagnosed with all conditions examined except schizophrenia, conduct disorder and opposition defiant disorder.

Table 2: Prevalence of Mental Health Diagnoses by Gender and Race

	Gender				Race					
	Male		Female		White		Black		Other	
POPULATION	207,593	47.98%	224,361	51.86%	144,322	3.36%	248,995	57.55%	39,337	9.09%
Diag↓	Count	% sex % diag	Count	% sex % diag	Count	% race % diag	Count	% race % diag	Count	% race % diag
Any MH Diag	31,535	15.19 61.28	19,923	8.88 38.72	20,413	14.14 39.67	23,178	9.31 45.04	7,869	20.00 15.29
ADD	20,460	9.86 70.44	8,586	3.83 29.56	12,445	8.62 42.84	11,948	4.80 41.13	4,654	11.83 16.02
Bipolar	3,896	1.88 58.14	2,805	1.25 41.86	2,893	2.00 43.17	2,637	1.06 39.35	1,171	2.98 17.48
Depression	2,818	1.36 39.76	4,270	1.90 60.24	3,222	2.23 45.46	2,969	1.19 41.89	897	2.28 12.66
Anxiety	3,872	1.87 44.71	4,789	2.13 55.29	4,177	2.89 48.23	3,528	1.42 40.73	956	2.43 11.04
Schizophrenia	943	0.45 54.99	772	0.34 45.01	399	0.28 23.27	941	0.38 54.87	375	0.95 21.87
Conduct	5,682	2.74 66.96	2,802	1.25 33.02	2,597	1.80 30.60	4,607	1.85 54.29	1,282	3.26 15.11
ODD	6,888	3.32 64.71	3,757	1.67 35.29	2,863	1.98 26.90	6,150	2.47 57.77	1,632	4.15 15.33
Learning	1,759	0.85 63.85	996	0.44 36.15	816	0.57 29.62	1,034	0.42 37.53	905	2.30 32.85
Autism	1,133	0.55 79.96	284	0.13 20.04	396	0.27 27.95	322	0.13 22.72	699	1.78 49.33

NOTE: The denomination is all beneficiaries 21 years or less on 12/31/2010 with a medical or prescription claim
(Total beneficiaries = 431,654)

Next Action:

Analysis is on-going. Once MS-DUR has been able to build a complete eligibility file, prevalence estimates will be updated. Additional analyses then be conducted to address all of the issues identified in the proposed analyses. A final report will be developed and submitted to DOM and recommendations for new edits, etc. that are warranted will be brought to the DUR Board at the next quarterly meeting.

DUR Board action at this time – Seeking comments and recommendations.

Potential Prescribing Outside of Prescriptive Authority

Background/Issue:


The Division of Medicaid wishes to gain a better understanding of the incidence of potential inappropriate prescribing among Medicaid providers with limited prescriptive authority, including podiatrists, optometrists, and dentists.

Analysis:

Therapeutic drug classes were categorized based on “prescriptive appropriateness” for the provider types identified as having limited prescriptive authority. These categorizations of “appropriateness” were based on regulatory guidance when available. Claims data from January 1, 2010 to June 30, 2011 were analyzed for the three provider types to determine the therapeutic categories which were being prescribed by each provider type. Therapeutic categories were classified as *clearly appropriate*, *possibly appropriate*, or *clearly inappropriate* from this initial list [See the Appendix]. The provider file was used to identify providers of interest and all POS claims written by these providers were pulled and analyzed. The target list of providers only included dentists, podiatrists and optometrists.

Preliminary Results:

Of the three selected provider types, a total of 974 providers were identified from the provider file. Using data from the NPI file the physicians were divided into 3 types depending on their specialty (using NPI taxonomy codes). These were dentists (taxonomy code 1223XXX), podiatrists (taxonomy code 213EXXX) and optometrists (taxonomy code 152WXXX). The distribution of these three specialties in the data is as follows:



The drug categories prescribed by these providers within the period of January 1, 2010 and June 30, 2011 were used in the analysis. Table 1 shows the percentage of prescriptions by classification class for each type of provider. Podiatrists had the greatest percentage of clearly inappropriate prescriptions.

Table 1 - Appropriateness of prescribing by provider type.

Table 1: Prevalence of Type of Prescribing for Each Provider Type			
Provider Type	Prescribing		
	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
Dentist	93.50%	2.98%	3.52%
Podiatrist	87.12%	3.61%	9.28%
Optometrist	95.96%	0.88%	3.16%

Although a vast majority of drugs prescribed by each of the provider types are appropriate, even the low numbers of possibly appropriate and clearly inappropriate drugs can have an adverse effect on patient health. Tables 2-4 show the frequency of prescriptions that were classified as possibly appropriate or clearly inappropriate for each specialty broken down by drug categories.

Table 2: Possibly Appropriate / Inappropriate Drugs prescribed by Dentists		
Dentists (N=135)		
Drug	Frequency	Percentage
Benzodiazepines	1774	7.88
Glucocorticoids	1481	6.58
Antihistamines	1257	5.58
Antihypertensive combinations	864	3.84
Upper respiratory combinations	795	3.53
Miscellaneous anxiolytics, sedatives and hypnotics	626	2.78
Topical steroids	622	2.76
Azole antifungals	593	2.63
Contraceptives	442	1.96
Tetracyclines	365	1.62
Vitamin and mineral combinations	360	1.60
Antiviral combinations	275	1.22
Iron products	236	1.05
Otic steroids with anti-infectives	200	0.89
Topical steroids with anti-infectives	200	0.89

Table 2: Possibly Appropriate / Inappropriate Drugs prescribed by Dentists		
Amebicides	188	0.83
Adrenergic bronchodilators	173	0.77
CNS stimulants	171	0.76
Skeletal muscle relaxants	160	0.71
Leukotriene modifiers	152	0.68
Topical anesthetics	120	0.53
Bronchodilator combinations	112	0.50
Insulin	110	0.49
Topical antibiotics	105	0.47
Topical antifungals	105	0.47
Quinolones	96	0.43
Protease inhibitors	93	0.41
Urinary anti-infectives	93	0.41
Proton pump inhibitors	83	0.37
Angiotensin converting enzyme inhibitors	75	0.33
Ophthalmic steroids with anti-infectives	75	0.33
HMG-CoA reductase inhibitors	71	0.32
Calcium channel blocking agents	71	0.32
Topical antivirals	71	0.32
Antiasthmatic combinations	68	0.30
Nasal steroids	66	0.29
Non-sulfonylureas	64	0.28
SSRI antidepressants	61	0.27
H2 antagonists	59	0.26
Miscellaneous antipsychotic agents	59	0.26
Antidiabetic combinations	56	0.25
Atypical antipsychotics	52	0.23
Ophthalmic anti-infectives	50	0.22
Miscellaneous otic agents	44	0.20
Hormones/antineoplastics	43	0.19
Purine nucleosides	42	0.19
Antidiarrheals	41	0.18
Antiadrenergic agents, centrally acting	36	0.16
Miscellaneous antifungals	36	0.16
Topical acne agents	35	0.16
Gamma-aminobutyric acid analogs	34	0.15
Inhaled corticosteroids	32	0.14
Cardioselective beta blockers	30	0.13
Non-cardioselective beta blockers	30	0.13
Hydantoin anticonvulsants	29	0.13
Vaginal anti-infectives	29	0.13
Ophthalmic antihistamines and decongestants	27	0.12
Estrogens	26	0.12
Sulfonylureas	25	0.11
Loop diuretics	24	0.11

Table 2: Possibly Appropriate / Inappropriate Drugs prescribed by Dentists		
Thiazide diuretics	24	0.11
SSNRI antidepressants	22	0.10
Integrase strand transfer inhibitor	21	0.09
5HT3 receptor antagonists	18	0.08
Neuraminidase inhibitors	18	0.08
Thyroid drugs	18	0.08
Barbiturates	17	0.08
Tricyclic antidepressants	16	0.07
Anticholinergic antiparkinson agents	15	0.07
Expectorants	15	0.07
Miscellaneous topical agents	15	0.07
Ophthalmic glaucoma agents	14	0.06
Antacids	13	0.06
Angiotensin II inhibitors	12	0.05
Laxatives	12	0.05
Miscellaneous hormones	12	0.05
Platelet aggregation inhibitors	12	0.05
NRTIs	11	0.05
Inotropic agents	11	0.05
Topical anti-infectives	11	0.05
Urinary antispasmodics	11	0.05
Carbonic anhydrase inhibitor anticonvulsants	10	0.04
Dibenzazepine anticonvulsants	10	0.04
Vitamins	10	0.04
H. pylori eradication agents	9	0.04
Antianginal agents	9	0.04
Antitussives	9	0.04
Coumarins and indandiones	9	0.04
Phenylpiperazine antidepressants	9	0.04
Potassium-sparing diuretics	9	0.04
Decongestants	8	0.04
Dipeptidyl peptidase 4 inhibitors	8	0.04
Heparins	8	0.04
Smoking cessation agents	8	0.04
Vasopressors	8	0.04
Miscellaneous coagulation modifiers	7	0.03
Anticholinergic bronchodilators	6	0.03
Antirheumatics	6	0.03
Methylxanthines	6	0.03
Miscellaneous genitourinary tract agents	6	0.03
Antigout agents	5	0.02
Immunosuppressive agents	5	0.02
Triazine anticonvulsants	5	0.02
GI stimulants	4	0.02
Fatty acid derivative anticonvulsants	4	0.02

Table 2: Possibly Appropriate / Inappropriate Drugs prescribed by Dentists		
Fibric acid derivatives	4	0.02
Leprostatics	4	0.02
Tetracyclic antidepressants	4	0.02
Antiadrenergic agents, peripherally acting	3	0.01
Antimetabolites	3	0.01
Miscellaneous GI agents	3	0.01
Nutraceutical products	3	0.01
Thiazolidinediones	3	0.01
Anticholinergics/antispasmodics	2	0.01
Antimigraine agents	2	0.01
Carbonic anhydrase inhibitors	2	0.01
Dopaminergic antiparkinsonism agents	2	0.01
Ophthalmic steroids	2	0.01
Phenothiazine antiemetics	2	0.01
Phenothiazine antipsychotics	2	0.01
Pyrrolidine anticonvulsants	2	0.01
Vasodilators	2	0.01
NNRTIs	1	0.00
Alpha-glucosidase inhibitors	1	0.00
Anthelmintics	1	0.00
Anticholinergic antiemetics	1	0.00
Group I antiarrhythmics	1	0.00
Miscellaneous antidepressants	1	0.00
Miscellaneous antimalarials	1	0.00
Mydriatics	1	0.00
Nasal antihistamines and decongestants	1	0.00
Otic anti-infectives	1	0.00
Topical debriding agents	1	0.00

Table 3: Possibly Appropriate / Inappropriate Drugs prescribed by Podiatrists

Podiatrists (N=47)		
Drug	Frequency	Percentage
Otic steroids with anti-infectives	543	33.42
Glucocorticoids	235	14.46
Gamma-aminobutyric acid analogs	173	10.65
Quinolones	93	5.72
Antihistamines	57	3.51
Ophthalmic glaucoma agents	57	3.51
Ophthalmic steroids with anti-infectives	49	3.02
Benzodiazepines	48	2.95
Miscellaneous topical agents	48	2.95
Skeletal muscle relaxants	33	2.03
Contraceptives	32	1.97
Tricyclic antidepressants	31	1.91
Vaginal anti-infectives	31	1.91
Antiadrenergic agents, centrally acting	29	1.78
Miscellaneous anxiolytics, sedatives and hypnotics	20	1.23
CNS stimulants	18	1.11
Upper respiratory combinations	16	0.98
Topical acne agents	11	0.68
Potassium-sparing diuretics	7	0.43
SSRI antidepressants	5	0.31
Insulin	5	0.31
Minerals and electrolytes	5	0.31
Atypical antipsychotics	4	0.25
Bile acid sequestrants	4	0.25
Intravenous nutritional products	4	0.25
Ophthalmic anti-infectives	4	0.25
Platelet aggregation inhibitors	4	0.25
Vitamin and mineral combinations	4	0.25
Adrenergic bronchodilators	3	0.18
Inhaled corticosteroids	3	0.18
Mouth and throat products	3	0.18
Rifamycin derivatives	3	0.18
Thiazide diuretics	3	0.18
Expectorants	2	0.12
Hormones/antineoplastics	2	0.12
Loop diuretics	2	0.12
Miscellaneous cardiovascular agents	2	0.12
Non-sulfonylureas	2	0.12
Angiotensin II inhibitors	1	0.06
Antianginal agents	1	0.06
Antitussives	1	0.06
Iron products	1	0.06
Miscellaneous coagulation modifiers	1	0.06

Table 3: Possibly Appropriate / Inappropriate Drugs prescribed by Podiatrists		
Phenylpiperazine antidepressants	1	0.06
Purine nucleosides	1	0.06
Smoking cessation agents	1	0.06

Table 4: Possibly Appropriate / Inappropriate Drugs prescribed by Optometrists		
Optometrists (N=76)		
Drug	Frequency	Percentage
Contraceptives	225	17.21
upper respiratory combinations	173	13.24
CNS stimulants	82	6.27
Antihistamines	76	5.81
antihypertensive combinations	44	3.37
purine nucleosides	42	3.21
insulin	40	3.06
leukotriene modifiers	35	2.68
glucocorticoids	32	2.45
urinary anti-infectives	29	2.22
adrenergic bronchodilators	25	1.91
SSRI antidepressants	24	1.84
benzodiazepines	23	1.76
proton pump inhibitors	23	1.76
topical steroids	22	1.68
carbonic anhydrase inhibitors	21	1.61
H2 antagonists	20	1.53
miscellaneous otic agents	20	1.53
quinolones	20	1.53
antidiabetic combinations	16	1.22
azole antifungals	16	1.22
nasal steroids	15	1.15
amebicides	14	1.07
calcium channel blocking agents	13	0.99
nutraceutical products	13	0.99
skeletal muscle relaxants	13	0.99
topical antifungals	12	0.92
topical steroids with anti-infectives	12	0.92
anticholinergics/antispasmodics	11	0.84
miscellaneous anxiolytics, sedatives and hypnotics	11	0.84
platelet aggregation inhibitors	11	0.84
5HT3 receptor antagonists	10	0.77
laxatives	10	0.77
HMG-CoA reductase inhibitors	9	0.69
antiviral combinations	9	0.69
antiasthmatic combinations	8	0.61
bronchodilator combinations	8	0.61
topical antibiotics	8	0.61
atypical antipsychotics	7	0.54
antirheumatics	6	0.46
expectorants	6	0.46
miscellaneous antifungals	6	0.46
hormones/antineoplastics	5	0.38

Table 4: Possibly Appropriate / Inappropriate Drugs prescribed by Optometrists		
non-cardioselective beta blockers	5	0.38
sulfonylureas	5	0.38
angiotensin converting enzyme inhibitors	4	0.31
antianginal agents	4	0.31
anticholinergic antiparkinson agents	4	0.31
cardioselective beta blockers	4	0.31
coumarins and indandiones	4	0.31
miscellaneous genitourinary tract agents	4	0.31
tetracyclic antidepressants	4	0.31
vaginal anti-infectives	4	0.31
antiadrenergic agents, centrally acting	3	0.23
hydantoin anticonvulsants	3	0.23
miscellaneous topical agents	3	0.23
mouth and throat products	3	0.23
neuraminidase inhibitors	3	0.23
smoking cessation agents	3	0.23
antidiarrheals	2	0.15
antitussives	2	0.15
miscellaneous antipsychotic agents	2	0.15
topical acne agents	2	0.15
topical antivirals	2	0.15
GI stimulants	1	0.08
anthelmintics	1	0.08
decongestants	1	0.08
gamma-aminobutyric acid analogs	1	0.08
inhaled corticosteroids	1	0.08
miscellaneous antidepressants	1	0.08
miscellaneous hormones	1	0.08
non-sulfonylureas	1	0.08
phenothiazine antiemetics	1	0.08
phenylpiperazine antidepressants	1	0.08
tricyclic antidepressants	1	0.08
urinary antispasmodics	1	0.08

Next Action:

Incorporate days supply into analysis to better evaluate potential appropriateness of prescriptions. Examine prescriptions written for family members and potential fraud where prescriptions are written repeatedly for the same person. MS-DUR will bring any needed recommendations for action to DUR Board at next quarterly meeting.

DUR Board action at this time - comments and recommendations.

**MISSISSIPPI MEDICAID
RETROSPECTIVE DRUG UTILIZATION REVIEW
EXCEPTIONS MONITORING CRITERIA RECOMMENDATIONS**

Criteria Recommendations**Approve Reject****1. Linezolid and SSRIs (etc)**

Description: On June 26, 2011 the FDA issued a drug safety communication warning prescribers of a potential interaction between Zyvox® (linezolid) and certain antidepressants and pain medicines. Post-marketing surveillance reports of serotonin syndrome have led to the warning.

Exception Type: Drug-drug interaction (DDI)

Object

linezolid

Precipitant

selective-serotonin reuptake inhibitors
tricyclic antidepressants
5HT-1 agonists (triptans)
meperidine
buspirone

References:

FDA Medwatch Safety Alert. "Zyvox (linezolid): Drug Safety Communication - Serious CNS Reactions Possible When Given to Patients Taking Certain Psychiatric Medications." [07/26/2011]

2. Co-administration of simvastatin with select drugs

Description: Due to an increased risk of myopathies, the dose of simvastatin should not exceed 10mg/day for patients taking amiodarone, verapamil, or diltiazem. Additionally, the dose of simvastatin should not exceed 20mg for individuals taking amlodipine or ranolazine.

Exception Type: Drug-drug interaction (DDI)

Object

amiodarone
verapamil
diltiazem
amlodipine
ranolazine

Precipitant

simvastatin >10mg
simvastatin >10mg
simvastatin >10mg
simvastatin >20mg
simvastatin >20mg

References:

Zocor® (simvastatin) Package Insert, July 2011, Merck, Inc.

3. High dose simvastatin increases risk of myopathies

Description: Patients receiving simvastatin 80mg at an increased risk of myopathy, including rhabdomyolysis.

Exception Type: Inappropriate dose (IDO)

References:

Zocor® (simvastatin) Package Insert, July 2011, Merck, Inc.

4. Persistence of beta-blocker treatment after a heart attack

Description: Measure of the proportion of beneficiaries who had a myocardial infarction that are persistent to beta-blocker therapy.

Exception Type: Clinical appropriateness (CAP)

Drug Class

beta-blockers

Disease Category

acute myocardial infarction

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

5. Statin therapy in patients with coronary artery disease

Description: Measure is the proportion of patients with coronary artery disease who received at least on prescription for a statin.

Exception Type: Clinical appropriateness (CAP)

Drug Class

statins

Disease Category

coronary artery disease

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

6. Use of appropriate medications for people with asthma _____

Description: Measure is the proportion of patients with persistent asthma who were dispensed an inhaled corticosteroid or similar medication during the measurement period.

Exception Type: Clinical appropriateness (CAP)

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

7. Persistence with antidepressant medications _____

Description: Measure is the proportion of patient on antidepressant therapy that are persistent with therapy for at least 6 months as endorsed by the National Committee for Quality Assurance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

selective-serotonin reuptake inhibitors (SSRI)
tricyclic antidepressants (TCAs)
phenothiazine combinations
monoamine-oxidase inhibitors (MAOIs)

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

8. Adherence with beta-blockers – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for beta-blockers as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

beta-blockers

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

9. Adherence with ACE inhibitors – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for ACE inhibitors as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

ACE inhibitors

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

10. Adherence with ARBs – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for angiotensin receptor blockers (ARBs) as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

angiotensin receptor blockers (ARBs)

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

11. Adherence with calcium channel blockers – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for calcium channel blockers as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

calcium channel blockers

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

12. Adherence with statins – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for statins as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

statins

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

13. Adherence with biguanides – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for biguanides as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

biguanides

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

14. Adherence with sulfonylureas – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for sulfonylureas as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

sulfonylureas

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

15. Adherence with thiazolidinediones (TZDs) – proportion of days covered _____

Description: Measure is the proportion of patients who met the proportion of days covered (PDC) threshold of 80% for thiazolidinediones (TZDs) as endorsed by the Pharmacy Quality Alliance and the National Quality Forum.

Exception Type: Appropriate Use (APU)

Drug Class

thiazolidinediones (TZDs)

References:

Department of Health and Human Services. CMS. Medicaid Program: Initial Core Set of Health Quality Measures for Medicaid-Eligible Adults. Federal Register. Volume 75, Number 250. Thursday, December 30, 2010. [CMS–2420–NC]. Pages 82397-82399.

Appendix

Dentists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
adrenal cortical steroids	glucocorticoids			X
alternative medicines	nutraceutical products			X
analgesics	analgesic combinations	X		
analgesics	antimigraine agents		X	
analgesics	miscellaneous analgesics	X		
analgesics	narcotic analgesic combinations	X		
analgesics	narcotic analgesics	X		
analgesics	nonsteroidal anti-inflammatory agents	X		
analgesics	salicylates	X		
antiarrhythmic agents	group I antiarrhythmics			X
anticoagulants	coumarins and indandiones			X
anticoagulants	heparins			X
anticonvulsants	carbonic anhydrase inhibitor anticonvulsants			X
anticonvulsants	dibenzazepine anticonvulsants			X
anticonvulsants	fatty acid derivative anticonvulsants			X
anticonvulsants	gamma-aminobutyric acid analogs			X
anticonvulsants	hydantoin anticonvulsants			X
anticonvulsants	pyrrolidine anticonvulsants			X
anticonvulsants	triazine anticonvulsants			X
antidepressants	miscellaneous antidepressants			X
antidepressants	phenylpiperazine antidepressants			X
antidepressants	SSNRI antidepressants			X
antidepressants	SSRI antidepressants			X
antidepressants	tetracyclic antidepressants			X
antidepressants	tricyclic antidepressants			X
antidiabetic agents	alpha-glucosidase inhibitors			X
antidiabetic agents	antidiabetic combinations			X
antidiabetic agents	dipeptidyl peptidase 4 inhibitors			X
antidiabetic agents	insulin			X
antidiabetic agents	non-sulfonylureas			X
antidiabetic agents	sulfonylureas			X
antidiabetic agents	thiazolidinediones			X
antiemetic/antivertigo agents	5HT3 receptor antagonists		X	
antiemetic/antivertigo agents	anticholinergic antiemetics			X

Dentists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
antiemetic/antivertigo agents	phenothiazine antiemetics		X	
antifungals	azole antifungals		X	
antifungals	miscellaneous antifungals		X	
antihyperlipidemic agents	fibric acid derivatives			X
antihyperlipidemic agents	HMG-CoA reductase inhibitors			X
anti-infectives	amebicides		X	
anti-infectives	anthelmintics		X	
anti-infectives	leprostatics			X
anti-infectives	lincomycin derivatives	X		
anti-infectives	miscellaneous antibiotics	X		
anti-infectives	quinolones			X
anti-infectives	tetracyclines			X
anti-infectives	urinary anti-infectives			X
antimalarial agents	miscellaneous antimalarials			X
antineoplastics	antimetabolites			X
antineoplastics	hormones/antineoplastics			X
antiparkinson agents	anticholinergic antiparkinson agents			X
antiparkinson agents	dopaminergic antiparkinsonism agents			X
antiplatelet agents	platelet aggregation inhibitors			X
antipsychotics	atypical antipsychotics			X
antipsychotics	miscellaneous antipsychotic agents			X
antipsychotics	phenothiazine antipsychotics			X
antiviral agents	antiviral combinations			X
antiviral agents	integrase strand transfer inhibitor			X
antiviral agents	neuraminidase inhibitors			X
antiviral agents	NNRTIs			X
antiviral agents	NRTIs			X
antiviral agents	protease inhibitors			X
antiviral agents	purine nucleosides			X
anxiolytics, sedatives, and hypnotics	barbiturates		X	
anxiolytics, sedatives, and hypnotics	benzodiazepines		X	
anxiolytics, sedatives, and hypnotics	miscellaneous anxiolytics, sedatives and hypnotics		X	

Dentists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
beta-adrenergic blocking agents	cardioselective beta blockers			X
beta-adrenergic blocking agents	non-cardioselective beta blockers			X
bronchodilators	adrenergic bronchodilators			X
bronchodilators	anticholinergic bronchodilators			X
bronchodilators	bronchodilator combinations			X
bronchodilators	methylxanthines			X
cardiovascular agents	angiotensin converting enzyme inhibitors			X
cardiovascular agents	angiotensin II inhibitors			X
cardiovascular agents	antiadrenergic agents, centrally acting			X
cardiovascular agents	antiadrenergic agents, peripherally acting			X
cardiovascular agents	antianginal agents			X
cardiovascular agents	antihypertensive combinations			X
cardiovascular agents	calcium channel blocking agents			X
cardiovascular agents	inotropic agents			X
cardiovascular agents	vasodilators			X
cardiovascular agents	vasopressors			X
central nervous system agents	CNS stimulants			X
cephalosporins	first generation cephalosporins	X		
cephalosporins	second generation cephalosporins	X		
cephalosporins	third generation cephalosporins	X		
coagulation modifiers	miscellaneous coagulation modifiers			X
dermatological agents	miscellaneous topical agents		X	
dermatological agents	topical acne agents			X
dermatological agents	topical anesthetics		X	
dermatological agents	topical antibiotics		X	
dermatological agents	topical antifungals		X	
dermatological agents	topical anti-infectives		X	
dermatological agents	topical antivirals		X	
dermatological agents	topical debriding agents		X	
dermatological agents	topical steroids		X	
dermatological agents	topical steroids with anti-infectives		X	
diuretics	carbonic anhydrase inhibitors			X

Dentists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
diuretics	loop diuretics			X
diuretics	potassium-sparing diuretics			X
diuretics	thiazide diuretics			X
functional bowel disorder agents	anticholinergics/antispasmodics			X
gastrointestinal agents	antacids		X	
gastrointestinal agents	antidiarrheals			X
gastrointestinal agents	GI stimulants			X
gastrointestinal agents	H. pylori eradication agents		X	
gastrointestinal agents	H2 antagonists		X	
gastrointestinal agents	laxatives			X
gastrointestinal agents	miscellaneous GI agents			X
gastrointestinal agents	proton pump inhibitors		X	
genitourinary tract agents	miscellaneous genitourinary tract agents			X
genitourinary tract agents	urinary antispasmodics			X
hormones	miscellaneous hormones			X
hormones	thyroid drugs			X
immunologic agents	immunosuppressive agents			X
macrolide derivatives	macrolides	X		
metabolic agents	antigout agents			X
miscellaneous agents	antirheumatics			X
miscellaneous agents	local injectable anesthetics	X		
miscellaneous agents	smoking cessation agents			X
muscle relaxants	skeletal muscle relaxants		X	
nasal preparations	nasal antihistamines and decongestants		X	
nasal preparations	nasal steroids		X	
nutritional products	iron products			X
nutritional products	minerals and electrolytes			X
nutritional products	vitamin and mineral combinations		X	
nutritional products	vitamins		X	
ophthalmic preparations	mydriatics			X
ophthalmic preparations	ophthalmic antihistamines and decongestants			X
ophthalmic preparations	ophthalmic anti-infectives			X
ophthalmic preparations	ophthalmic glaucoma agents			X
ophthalmic preparations	ophthalmic steroids			X
ophthalmic preparations	ophthalmic steroids with anti-infectives			X

Dentists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
otic preparations	miscellaneous otic agents			X
otic preparations	otic anti-infectives			X
otic preparations	otic steroids with anti-infectives			X
penicillins	aminopenicillins	X		
penicillins	beta-lactamase inhibitors	X		
penicillins	natural penicillins	X		
respiratory agents	antiasthmatic combinations			X
respiratory agents	antihistamines		X	
respiratory agents	antitussives			X
respiratory agents	decongestants		X	
respiratory agents	expectorants			X
respiratory agents	leukotriene modifiers			X
respiratory agents	upper respiratory combinations		X	
respiratory inhalant products	inhaled corticosteroids			X
sex hormones	contraceptives			X
sex hormones	estrogens			X
topical agents	antiseptic and germicides		X	
topical agents	mouth and throat products	X		
vaginal preparations	vaginal anti-infectives			X

Podiatrists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
adrenal cortical steroids	glucocorticoids		X	
analgesics	analgesic combinations	X		
analgesics	cox-2 inhibitors	X		
analgesics	miscellaneous analgesics	X		
analgesics	narcotic analgesic combinations	X		
analgesics	narcotic analgesics	X		
analgesics	nonsteroidal anti-inflammatory agents	X		
anticonvulsants	gamma-aminobutyric acid analogs			X
antidepressants	phenylpiperazine antidepressants			X
antidepressants	SSRI antidepressants			X
antidepressants	tricyclic antidepressants			X
antidiabetic agents	insulin			X
antidiabetic agents	non-sulfonylureas			X
antifungals	azole antifungals	X		
antifungals	miscellaneous antifungals	X		
antihyperlipidemic agents	bile acid sequestrants			X
anti-infectives	amebicides	X		
anti-infectives	lincomycin derivatives	X		
anti-infectives	miscellaneous antibiotics	X		
anti-infectives	quinolones			X
anti-infectives	tetracyclines	X		
antineoplastics	hormones/antineoplastics			X
antiplatelet agents	platelet aggregation inhibitors			X
antipsychotics	atypical antipsychotics			X
antituberculosis agents	rifamycin derivatives			X
antiviral agents	purine nucleosides			X
anxiolytics, sedatives, and hypnotics	benzodiazepines		X	
anxiolytics, sedatives, and hypnotics	miscellaneous anxiolytics, sedatives and hypnotics		X	
bronchodilators	adrenergic bronchodilators			X
cardiovascular agents	angiotensin II inhibitors			X
cardiovascular agents	antiadrenergic agents, centrally acting		X	
cardiovascular agents	antianginal agents		X	
cardiovascular agents	miscellaneous cardiovascular agents		X	
central nervous system agents	CNS stimulants			X

Podiatrists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
cephalosporins	first generation cephalosporins	X		
cephalosporins	second generation cephalosporins	X		
coagulation modifiers	miscellaneous coagulation modifiers			X
dermatological agents	miscellaneous topical agents		X	
dermatological agents	topical acne agents		X	
dermatological agents	topical anesthetics	X		
dermatological agents	topical antibiotics	X		
dermatological agents	topical antifungals	X		
dermatological agents	topical anti-infectives	X		
dermatological agents	topical debriding agents	X		
dermatological agents	topical emollients	X		
dermatological agents	topical steroids	X		
dermatological agents	topical steroids with anti-infectives	X		
diuretics	loop diuretics			X
diuretics	potassium-sparing diuretics			X
diuretics	thiazide diuretics			X
gastrointestinal agents	H2 antagonists		X	
macrolide derivatives	macrolides	X		
metabolic agents	antigout agents	X		
miscellaneous agents	smoking cessation agents			X
muscle relaxants	skeletal muscle relaxants		X	
nutritional products	intravenous nutritional products			X
nutritional products	iron products		X	
nutritional products	minerals and electrolytes		X	
nutritional products	vitamin and mineral combinations			X
ophthalmic preparations	ophthalmic anti-infectives			X
ophthalmic preparations	ophthalmic glaucoma agents			X
ophthalmic preparations	ophthalmic steroids with anti-infectives			X
otic preparations	otic steroids with anti-infectives			X
penicillins	aminopenicillins	X		
penicillins	beta-lactamase inhibitors	X		
penicillins	natural penicillins	X		
penicillins	penicillinase resistant penicillins	X		
respiratory agents	antihistamines			X
respiratory agents	antitussives			X
respiratory agents	expectorants			X
respiratory agents	upper respiratory combinations			X

Podiatrists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
respiratory inhalant products	inhaled corticosteroids			X
sex hormones	contraceptives			X
topical agents	antiseptic and germicides	X		
topical agents	mouth and throat products			X
vaginal preparations	vaginal anti-infectives			X

Optometrists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
adrenal cortical steroids	glucocorticoids		X	
alternative medicines	nutraceutical products			X
analgesics	analgesic combinations	X		
analgesics	miscellaneous analgesics	X		
analgesics	narcotic analgesic combinations	X		
analgesics	narcotic analgesics	X		
analgesics	nonsteroidal anti-inflammatory agents	X		
analgesics	salicylates	X		
anticoagulants	coumarins and indandiones			X
anticonvulsants	gamma-aminobutyric acid analogs			X
anticonvulsants	hydantoin anticonvulsants			X
antidepressants	miscellaneous antidepressants			X
antidepressants	phenylpiperazine antidepressants			X
antidepressants	SSRI antidepressants			X
antidepressants	tetracyclic antidepressants			X
antidepressants	tricyclic antidepressants			X
antidiabetic agents	antidiabetic combinations			X
antidiabetic agents	insulin			X
antidiabetic agents	non-sulfonylureas			X
antidiabetic agents	sulfonylureas			X
antiemetic/antivertigo agents	5HT3 receptor antagonists			X
antiemetic/antivertigo agents	phenothiazine antiemetics		X	
antifungals	azole antifungals			X
antifungals	miscellaneous antifungals			X
antihyperlipidemic agents	HMG-CoA reductase inhibitors			X
anti-infectives	amebicides		X	
anti-infectives	anthelmintics		X	
anti-infectives	lincomycin derivatives	X		
anti-infectives	miscellaneous antibiotics	X		
anti-infectives	quinolones			X
anti-infectives	tetracyclines	X		
anti-infectives	urinary anti-infectives			X
antineoplastics	hormones/antineoplastics			X
antiparkinson agents	anticholinergic antiparkinson agents			X
antiplatelet agents	platelet aggregation inhibitors			X
antipsychotics	atypical antipsychotics			X
antipsychotics	miscellaneous antipsychotic agents			X
antiviral agents	antiviral combinations			X

Optometrists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
antiviral agents	neuraminidase inhibitors			X
antiviral agents	purine nucleosides			X
anxiolytics, sedatives, and hypnotics	benzodiazepines		X	
anxiolytics, sedatives, and hypnotics	miscellaneous anxiolytics, sedatives and hypnotics		X	
beta-adrenergic blocking agents	cardioselective beta blockers		X	
beta-adrenergic blocking agents	non-cardioselective beta blockers		X	
bronchodilators	adrenergic bronchodilators			X
bronchodilators	bronchodilator combinations			X
cardiovascular agents	angiotensin converting enzyme inhibitors			X
cardiovascular agents	antiadrenergic agents, centrally acting			X
cardiovascular agents	antianginal agents			X
cardiovascular agents	antihypertensive combinations			X
cardiovascular agents	calcium channel blocking agents			X
central nervous system agents	CNS stimulants			X
cephalosporins	first generation cephalosporins	X		
cephalosporins	second generation cephalosporins	X		
cephalosporins	third generation cephalosporins	X		
dermatological agents	miscellaneous topical agents		X	
dermatological agents	topical acne agents			X
dermatological agents	topical antibiotics		X	
dermatological agents	topical antifungals		X	
dermatological agents	topical antivirals		X	
dermatological agents	topical steroids		X	
dermatological agents	topical steroids with anti-infectives		X	
diuretics	carbonic anhydrase inhibitors		X	
functional bowel disorder agents	anticholinergics/antispasmodics		X	
gastrointestinal agents	5-aminosalicylates			X
gastrointestinal agents	antidiarrheals			X
gastrointestinal agents	GI stimulants			X
gastrointestinal agents	H2 antagonists			X
gastrointestinal agents	laxatives			X
gastrointestinal agents	proton pump inhibitors			X
genitourinary tract agents	miscellaneous genitourinary tract agents			X

Optometrists				
Drug Category Name	Drug Subcategory Name	Clearly Appropriate	Possibly Appropriate	Clearly Inappropriate
genitourinary tract agents	urinary antispasmodics			X
hormones	miscellaneous hormones			X
macrolide derivatives	macrolides	X		
miscellaneous agents	antirheumatics			X
miscellaneous agents	smoking cessation agents			X
muscle relaxants	skeletal muscle relaxants		X	
nasal preparations	nasal steroids		X	
nutritional products	iron products		X	
ophthalmic preparations	mydriatics	X		
ophthalmic preparations	ophthalmic antihistamines and decongestants	X		
ophthalmic preparations	ophthalmic anti-infectives	X		
ophthalmic preparations	ophthalmic anti-inflammatory agents	X		
ophthalmic preparations	ophthalmic glaucoma agents	X		
ophthalmic preparations	ophthalmic lubricants and irrigations	X		
ophthalmic preparations	ophthalmic steroids	X		
ophthalmic preparations	ophthalmic steroids with anti-infectives	X		
otic preparations	miscellaneous otic agents			X
penicillins	aminopenicillins	X		
penicillins	beta-lactamase inhibitors	X		
penicillins	natural penicillins	X		
penicillins	penicillinase resistant penicillins	X		
respiratory agents	antiasthmatic combinations			X
respiratory agents	antihistamines		X	
respiratory agents	antitussives			X
respiratory agents	decongestants			X
respiratory agents	expectorants			X
respiratory agents	leukotriene modifiers			X
respiratory agents	upper respiratory combinations			X
respiratory inhalant products	inhaled corticosteroids			X
sex hormones	contraceptives			X
topical agents	mouth and throat products			X
vaginal preparations	vaginal anti-infectives			X